



## Association between patients' beliefs about medicines and adherence to drug treatment after stroke

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003551
Article Type:	Research
Date Submitted by the Author:	04-Jul-2013
Complete List of Authors:	Sjölander, Maria; Umeå University, Department of Pharmacology and Clinical Neuroscience; Umeå University, Department of Public Health and Clinical Medicine Eriksson, Marie; Umeå University, Department of Statistics Glader, Eva-Lotta; Umeå University, Department of Public Health and Clinical Medicine
<b>Primary Subject Heading</b>:	Pharmacology and therapeutics
Secondary Subject Heading:	Patient-centred medicine
Keywords:	STROKE MEDICINE, CLINICAL PHARMACOLOGY, PREVENTIVE MEDICINE, THERAPEUTICS

SCHOLARONE™  
Manuscripts

1  
2  
3 Title: Association between patients' beliefs about medicines and adherence to drug treatment after  
4 stroke  
5  
6  
7

8 Corresponding author:  
9

10 Maria Sjölander, MPH  
11

12 Department of Public Health and Clinical Medicine/Department of Pharmacology and Clinical  
13 Neuroscience  
14

15 Umeå University  
16

17 S-901 87 Umeå  
18

19 Sweden  
20

21 Telephone +46 90 7853904, Fax +46 90 120430  
22

23 [maria.sjolander@pharm.umu.se](mailto:maria.sjolander@pharm.umu.se)  
24  
25  
26  
27

28 Marie Eriksson, PhD  
29

30 Department of Statistics, Umeå School of Business and Economics  
31

32 Umeå University  
33

34 Umeå, Sweden  
35  
36  
37

38 Eva-Lotta Glader, MD  
39

40 Department of Public Health and Clinical Medicine  
41

42 Umeå University  
43

44 Umeå, Sweden  
45  
46  
47

48 Keywords: stroke prevention, medication adherence, medication beliefs, illness perception,  
49

50 Word count: 3246  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

Objectives: Adherence to preventive drug treatment is a clinical problem and we hypothesized that patients' beliefs about medicines and stroke are associated with adherence. The objective was to examine associations between stroke patients' beliefs about stroke and drug treatment and their adherence to drug treatment.

Design: Cross-sectional questionnaire survey.

Setting: Stroke patients from 25 Swedish hospitals were included.

Measurements: Questionnaires were sent to 989 patients to assess their perceptions about stroke (Brief Illness Perception Questionnaire, Brief IPQ), beliefs about medicines (Beliefs about Medicines Questionnaires, BMQ), and adherence to treatment (Medication Adherence Report Scale, MARS) 3 months after stroke onset. Only patients living at home were included in the analysis. The primary outcome was self reported adherence as measured on MARS. MARS scores were dichotomized into adherent/non-adherent. Background and clinical data from the Swedish Stroke register were included.

Results: Eight hundred eleven patients were still living at home and 595 answered the questionnaire. Complete MARS data was available for 578 patients, and 72 (12.5 %) of these were classified as non-adherent. Non-adherent patients scored lower on positive beliefs as measured on BMQ-Necessity (Odds ratio (OR) = 0.90, 95% CI 0.83–0.98) and BMQ-Benefit (OR = 0.77, 95% CI 0.68–0.87), and higher on negative beliefs as measured on BMQ-Concern (OR = 1.12, 95% CI 1.05–1.21), BMQ-Overuse (OR = 1.29, 95% CI 1.14–1.45), and BMQ-Harm (OR = 1.12, 95% CI 1.01–1.24). The Brief IPQ showed that non-adherent patients believed their current treatment to be less useful ( $p = 0.001$ ).

Conclusions: This study showed associations between Swedish stroke patients' beliefs about medicines and adherence. Positive beliefs were less common and negative more common among non-adherent. To improve adherence, patients' beliefs about medicines should be considered.

## ARTICLE SUMMARY

### Article focus

- Poor patient adherence to secondary preventive drug treatment after stroke is a clinical problem.
- The objectives of this study were to examine stroke patients' beliefs about stroke and drug treatment after stroke, and to investigate if these beliefs are associated with patients' adherence to drug treatment after stroke

### Key messages

- There were associations between stroke patients' beliefs about medicines and non-adherence.
- Non-adherent patients scored lower on positive beliefs about medicines and higher on negative beliefs.
- Patients' personal beliefs need to be considered when prescribing medicines or trying to improve patients' use of medicines.

### Strengths and limitations of this study

- Validated questionnaires have been used to collect data on a large sample of patients.
- Although only a minority of patients reported non-adherent behaviour, associations between beliefs and adherence were statistically significant.
- The cross-sectional design made it impossible to draw conclusions about causality.

## INTRODUCTION

Stroke is the third leading cause of death in Sweden and causes great suffering among survivors and claims vast amounts of resources. Preventive treatment is of great importance, and secondary preventive drug treatment is recommended to most stroke patients to prevent recurrent strokes.[1] Patients' adherence to prescribed long-term and/or preventive treatment has, however, been shown to be low,[2] and this results in poor treatment outcomes in non-adherent patients.[3] A previous study on Swedish stroke patients showed that between 25% and 50% of patients, depending on the type of drug, discontinue secondary preventive drug treatment within 2 years after a stroke.[4]

Many factors have been tested for predictability of adherence.[5] Some treatment or healthcare related factors, such as simplified dosage regimens or satisfaction with health care, have been found to associate with a higher degree of adherence. It has been more difficult to find consistent associations between demographics and psycho-social factors and adherence, possibly because of interactions between factors.[5]

Several theoretical models have been developed to explain associations between psychological factors and health-related behaviour in general and adherence behaviour specifically. The model most often discussed in relation to patient adherence is Howard Leventhal's self-regulatory model (SRM).[6] According to an extended version of the SRM, both beliefs about medicines and illness perceptions are related to adherence.[7-9] Non-adherence is often assumed to be involuntary or unintentional – that patients forget, are unable to handle, or cannot afford the drug – but non-adherence is also quite often based on a decision, sometimes called 'intentional non-adherence'.[10] Intentional non-adherence is based on personal beliefs of possible risks from the disease itself, possible risks from the treatment, and with perceived need of the treatment.

Interventions to improve patients' long-term use of drugs are, although often complex, not very effective.[11] Preventive drug therapy after stroke is both a long-term and asymptomatic treatment, and to improve adherence it might be important to consider patients' beliefs about medicines and stroke. We hypothesized that patients' beliefs about medicines and stroke are associated with drug adherence among stroke patients. The objectives of this study were to examine stroke patients' beliefs about stroke and drug treatment after stroke, and to investigate if these beliefs are associated with patients' adherence to drug treatment after stroke.

## METHODS

In this cross-sectional study, questionnaire data on attitudes and beliefs about stroke and medicines has been merged with clinical data from the Swedish stroke register (Riks-Stroke). The study questionnaire and the follow-up questionnaire from the stroke register were sent to the patients 3 months after stroke onset.

The participants in this study were all stroke patients who were registered in Riks-Stroke from December 2011 to March 2012. Riks-Stroke was established in 1994, and since 1998 all hospitals that admit acute stroke patients report to the register.[12] In 2011, the register was estimated to cover 90.5% of all stroke cases in Sweden. All 74 hospitals participating in the stroke register were invited to participate and 25 of the hospitals volunteered. The participating hospitals are situated in 15 of the 21 counties/regions in Sweden and represent both rural and urban areas. University hospitals (n = 4), large non-university hospitals (n = 11), and community hospitals (n = 10) were included.

Only patients who, according to the stroke register, were living at home 3 months after they had suffered their stroke were included in the study. For other patients, such as patients living in institutions, non-individual routines were assumed to have too much of an effect on patient adherence.

Background information on the patient and information about the stroke event was obtained from Riks-Stroke through the patient's personal identification number. Intracerebral haemorrhages, cerebral infarctions, and strokes not specified as haemorrhage or infarction (diagnosis codes ICD-10: I61, I63, and I64) are included in Riks-Stroke. The register contains patient-related information and data about care both from the acute phase of the stroke and from a 3-month follow-up questionnaire.

Data on patients' beliefs about stroke, medicines, and patient adherence to treatment were collected through a questionnaire consisting of 35 questions with answers on Likert-type scales. The following three validated questionnaires were used in our study: the Brief Illness Perception Questionnaire (Brief IPQ), the Beliefs about Medicines Questionnaires (BMQ), and the Medication Adherence Report Scale (MARS).

The Brief IPQ consists of nine questions aimed at examining patients' cognitive and emotional ideas about their disease.[13] The Brief IPQ has been tested in several illness groups and shows reliability and validity.[13] For this study, questions have been modified to be more specific to stroke (e.g. replacing the word "illness" with "stroke"), and the face validity of the translation to Swedish was tested on a sample of Swedish stroke patients. The answers to the first eight questions in the Brief IPQ that were used in this study (Table 1) were rated on a scale from 0 to 10. The last question in the Brief IPQ is open-ended to assess what patients believe are the three most important causes of their stroke, but this question would have required qualitative analysis and, therefore, was not used.

**Table 1** Back-translation of the questions in the modified Brief Illness Perception Questionnaire

Question Nr	Back-translation of the questions in the modified Brief Illness Perception Questionnaire
1	How much does your stroke affect your life?
2	How long do you think your stroke will affect you?

3	How much control do you feel you have over your stroke/stroke symptoms?
4	How much do you think your treatment can prevent another stroke?
5	How much do you experience symptoms from your stroke?
6	How concerned are you about having another stroke?
7	How much do you think you know about stroke?
8	How much does your stroke affect you emotionally? (e.g. does it make you angry, scared, upset or depressed?)

The BMQ has been developed to assess personal beliefs about medicines.[14, 15] BMQ-Specific assesses patients' beliefs about drugs prescribed for their personal use, and BMQ-General assesses beliefs about medicines in general. The BMQ-Specific has two subscales (*Necessity* and *Concern*) with five questions each, and the BMQ-General has three subscales (*Harm*, *Overuse* and *Benefit*) with four questions each. Representations of the different BMQ subscales are presented in Table 2. Answers to all 22 questions were scored on a 5-point Likert scale (1 = strongly disagree, 2 = disagree, 3 = uncertain, 4 = agree, 5 = strongly agree) and a total score per BMQ scale was calculated. For individuals with one or more answers missing, the total scores of the corresponding BMQ subscales were excluded.

**Table 2** Representations of the different questionnaire subscales used to assess patients' beliefs about medicines.

BMQ-Subscales	Representation of personal beliefs
BMQ-Specific	
- Necessity	perceived personal need for medicine to maintain or improve own health
- Concern	perceived concern about negative effects of their own use of medicines
BMQ-General	
- Harm	perceived harmful nature of medicines in general
- Overuse	perceived notion that doctors overuse or put too much trust in medicines
- Benefit	perceived potential benefits of medicines in general

Self-rated non-adherence to treatment was the main outcome of this study, and this was assessed using the 5-item version of the MARS.[16] MARS and BMQ have previously been translated into Swedish with back-translation approved by the developer of the original questionnaires. The MARS-5 consists of five general statements about non-adherent behaviour (*I forget to take my medicines, I alter the dose of my medicines, I stop taking my medicines for a while, I decide to miss out a dose, I take less than instructed*) answered on a 5-point Likert scale (1 = *always*, 2 = *often*, 3 = *sometimes*, 4 = *rarely*, 5 = *never*). The outcome variable was calculated as the total score on the MARS-5 and a score of 5–22 was considered non-adherent and a score of 23–25 was considered adherent. Sensitivity analyses were performed with MARS scores 21 and 20 as the cut-off for non-adherence. Individuals missing one or more answers on the MARS were excluded from the analysis because their total MARS score would not be comparable with the rest of the study population.

#### Power calculation

1  
2  
3 The main hypothesis of the study was that there is a difference in BMQ between adherent and non-  
4 adherent patients as defined by their MARS score. Including 388 individuals, of whom approximately  
5 half are adherent, gives the study 80% power to detect a difference of 0.2 (BMQ) between adherent  
6 and non-adherent patients if the standard deviation for the difference is 0.7. This calculation is based  
7 on a 2-tailed t-test and a significance level of 0.05. To compensate for an ordinal response variable  
8 (BMQ) and a possible non-response (up to 40%), at least 650 individuals needed to be sent a  
9 questionnaire.  
10

### 11 **Statistical analyses**

12  
13 Differences in background and medical factors were tested using the Chi-squared test. The factors  
14 tested were age, sex, type of stroke, low level of consciousness at admission to hospital, history of  
15 stroke, and stroke unit treatment, and the factors from the 3 month follow-up were living alone,  
16 smoking, self-reported bad general health, self-reported depression, whether dependent on help  
17 and/or support from relatives, having had a return visit to a doctor and/or nurse, and self-reported  
18 difficulties with memory. Age was coded as <75 years or ≥75 years, sex as “Man” or “Woman”, type  
19 of stroke as “Haemorrhage” or “Other”, and difficulties with memory as “Never/almost never”,  
20 “Sometimes”, and “Often/constantly”. Answers to all other factors were coded “No” or “Yes”.  
21 Factors with a statistically significant difference ( $p < 0.05$ ) between adherent and non-adherent  
22 patients were included in multivariable analyses.  
23  
24

25  
26 The results for individual Brief IPQ questions and BMQ subscales were calculated as medians and  
27 inter quartile ranges (IQR). Mann-Whitney U tests were used to test differences between adherent  
28 and non-adherent patients in illness perceptions (individual items in the Brief IPQ) and beliefs about  
29 medicines (BMQ subscales).  
30  
31

32  
33 Besides descriptive analyses with group comparisons, the statistical analysis also included  
34 multivariable methods to control for several factors simultaneously. The outcome measure (self  
35 reported adherence as measured with MARS) was dichotomised, and logistic regression was used for  
36 multivariable analyses. For categorical co-variables, “<75 years”, “Man”, “Haemorrhage”,  
37 “Never/almost never” having difficulties with memory, and “No” were chosen as reference  
38 categories. After checking the linearity assumption, the Brief IPQ scores and the BMQ scores were  
39 included as continuous covariates in the logistic regression models. Results are presented as odds  
40 ratios (OR) with 95% confidence intervals (CI). Only one BMQ scale at a time was included in the  
41 regression models because the objective was to study associations between different beliefs about  
42 medicines and adherence. Spearman’s correlation coefficient was used to test for correlations  
43 between the different BMQ subscales.  
44  
45

46  
47 An analysis of non-responders was performed using data from the stroke register. Non-responders  
48 were compared by Chi-squared test to responders in regards to the same background and medical  
49 factors as described above.  
50  
51

52  
53 Internal consistency within BMQ subscales and MARS was measured with Cronbach’s alpha. A high  
54 value indicates high intercorrelation between items in a subscale, and values over 0.7 are considered  
55 acceptable.[17]  
56

57  
58 Statistical analyses were performed using IBM SPSS Statistics version 21.0  
59  
60



**Ethics**


This study was approved by the Ethical Review Board at Umeå University on January 17, 2012, Reg. No 2011-375-31M.

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## RESULTS

The study questionnaire was sent to 989 patients who were discharged from hospital to their own homes. Of these, 811 were living at home 3 months after their stroke and were included for further analysis. Out of these 811, 595 (73.4 %) responded to the questionnaire. Figure 1 shows a flowchart of hospitals and patients in the study.



**Figure 1** Flowchart of hospitals and patients in the study

Five hundred seventy-eight patients had complete answers to the adherence questions (MARS), and 72 (12.5 %) of these were classified as non-adherent. The proportion of patients who self-reported non-adherent behaviour (the answers “sometimes”, “often”, and “always”) on any of the MARS statements were 9.7% for “I forget to take my medicines”, 12.8% for “I alter the dose of my medicines”, 2.2% for “I stop taking my medicines for a while”, 8.4% for “I decide to miss out on a dose”, and 4.5% for “I take less than instructed”.

Differences in background and medical factors between adherent and non-adherent patients are presented in Table 3. Non-adherent patients were more often men, not treated in stroke units, dependent on the help and support from relatives, had a history of stroke, and more often self-reported memory difficulties compared to adherent patients.

**Table 3** Patient characteristics by level of adherence. Chi-squared test of differences between non-adherent and adherent patients.

<i>Variable/Characteristic</i>	<i>Non-adherent (n = 72)</i>	<i>Adherent (n = 506)</i>	<i>p</i>
Age, n (%)			0.341
- < 75 years	38 (11.3)	297 (88.7)	
- ≥ 75 years	34 (14.0)	209 (86.0)	
Sex, n (%)			0.042
- Men	51 (14.7)	295 (85.3)	
- Women	21 (9.1)	211 (90.9)	
Type of stroke, n (%)			0.325
- Haemorrhage	3 (7.5)	37 (92.5)	
- Other (ICD10 I63 + I64)	69 (12.8)	469 (87.2)	
Low level of consciousness at admission, n (%)			0.770
- No	68 (12.4)	480 (87.6)	
- Yes (Drowsy or unconscious)	4 (14.3)	24 (85.7)	
History of stroke, n (%)			0.010
- No	54 (11.0)	437 (89.0)	
- Yes	18 (20.9)	68 (79.1)	
Treated in stroke unit, n (%)			0.016
- No	6 (30.0)	14 (70.0)	
- Yes	66 (11.8)	491 (88.2)	
<b>3 months follow-up</b>			
Living alone, n (%)			0.241
- No	45 (11.2)	357 (88.8)	
- Yes	25 (14.7)	145 (85.3)	
Smoking, n (%)			0.303
- No	64 (12.1)	463 (87.9)	
- Yes	8 (17.4)	38 (82.6)	
Self-reported bad general health, n (%)			0.210
- No	56 (11.6)	426 (88.4)	
- Yes	14 (16.5)	71 (83.5)	
Self-reported depression, n (%)			0.147
- No	51 (11.4)	396 (88.6)	
- Yes	18 (16.5)	91 (83.5)	
Dependent on help/support from relatives, n (%)			0.015
- No	26 (9.0)	263 (91.0)	
- Yes	43 (15.8)	230 (84.2)	
Return visit, n (%)			0.521
- No	7 (9.9)	64 (90.1)	
- Yes	60 (12.5)	419 (87.5)	
Difficulties with memory, n (%)			0.014
- Never or almost never	25 (11.1)	200 (88.9)	
- Sometimes	29 (10.7)	241 (89.3)	
- Often or constantly	17 (23.0)	57 (77.0)	

Internal consistency for BMQ subscales and MARS, measured by Cronbach's alpha, showed highest values for the BMQ-Specific scales (Table 4).

**Table 4** Descriptive of questionnaire scales used.

<i>Scale</i>	<i>Number of items in scale</i>	<i>Range of scores</i>	<i>Cronbach's alpha</i>
BMQ-Specific			
- Necessity	5	5-25	0.823
- Concern	5	5-25	0.818
BMQ-General			
- Overuse	4	4-20	0.684
- Harm	4	4-20	0.647
- Benefit	4	4-20	0.697
MARS	5	5-25	0.723

Results from question 4 on the modified Brief IPQ "How much do you think your current treatment can prevent another stroke?" showed that non-adherent patients believed their current treatment to be less useful (median = 5 (IQR 3–7)) compared to adherent patients (median = 7 (IQR 5–8)) and this difference was statistically significant ( $p = 0.001$ ). No other Brief IPQ-question showed a significant difference between adherent and non-adherent patients.

Results for total BMQ scale scores are presented and compared in Table 5. All BMQ subscales except *Necessity* showed statistically significant differences between adherent and non-adherent patients in the univariate analysis.

**Table 5** Scale score medians and inter quartile ranges (IQR) for the scales used to assess patients' beliefs about medicines (BMQ), comparing non-adherent with adherent patients.

<i>Variable</i>	<i>Valid cases (n = 578)</i>	<i>Scale score median (IQR)</i>		<i>Mann-Whitney U test (p-value)</i>	<i>Adjusted with multivariable logistic regression* OR for a one-unit increase (95% CI)</i>
		<i>Non-Adherent</i>	<i>Adherent</i>		
BMQ-Specific					
- Necessity	558	18 (16-20)	19 (17-21)	0.079	0.90 (0.83-0.98)
- Concern	552	14 (11-17)	12 (9-15)	<0.001	1.12 (1.05-1.21)
BMQ-General					
- Overuse	556	13 (11-14)	11 (10-13)	<0.001	1.29 (1.14-1.45)
- Harm	544	11 (9-12.25)	10 (8-12)	0.038	1.12 (1.01-1.24)
- Benefit	560	16 (14-16)	16 (15-18)	<0.001	0.77 (0.68-0.87)

\* Adjusted for age, sex, history of stroke, if treated in stroke unit, dependent on help/support from relatives, difficulties with memory, Brief IPQ – question 4, and respective BMQ subscale.

The multivariable logistic regression models showed associations between all five subscales on beliefs about medicines and non-adherence to treatment. Non-adherent stroke patients had lower

scores on the positive statements about medicines as measured on both BMQ subscales *Necessity* (OR = 0.90, 95% CI 0.83–0.98) and *Benefit* (OR = 0.77, 95% CI 0.68–0.87). Non-adherent patients also scored higher on the negative beliefs as measured on BMQ subscales *Concern* (OR = 1.12, 95% CI 1.05–1.21), *Harm* (OR = 1.12, 95% CI 1.01–1.24), and *Overuse* (OR = 1.29, 95% CI 1.14–1.45). Correlations between the different BMQ subscales were statistically significant except between *Necessity* and *Concern* (Table 6).

**Table 6** Correlation matrix for different scales used to test beliefs about medicines. Spearman's correlation coefficient (p-value).

	BMQ- Necessity	BMQ- Concern	BMQ- Overuse	BMQ- Harm	BMQ- Benefit
BMQ- Necessity	1				
BMQ- Concern	-0.075 (0.080)	1			
BMQ- Overuse	-0.226 (<0.001)	0.434 (<0.001)	1		
BMQ- Harm	-0.185 (<0.001)	0.444 (<0.001)	0.558 (<0.001)	1	
BMQ- Benefit	0.315 (<0.001)	-0.287 (<0.001)	-0.322 (<0.001)	-0.362 (<0.001)	1

Out of the 356 non-responders, 216 were still living at home 3 months after the stroke onset. Patients who responded to the questionnaire were compared to non-responders in terms of background and medical factors (the same factors were tested as in Table 3). The results of this analysis showed that non-responders more often had a history of stroke ( $p = 0.018$ ), self-reported bad general health ( $p = 0.001$ ), depression ( $p = 0.012$ ), were living alone ( $p = <0.001$ ), and were smoking ( $p = 0.046$ ). Non-responders had been treated in university hospitals ( $n = 27$ ), large non-university hospitals ( $n = 140$ ), and community hospitals ( $n = 49$ ).

The variables from Riks-Stroke with the highest numbers of missing data were, for responders ( $n = 595$ ), return visits ( $n = 28$ ) and self-reported depression ( $n = 22$ ), and for non-responders ( $n = 216$ ), return visits ( $n = 18$ ) and self-reported depression ( $n = 14$ ).

Sensitivity analyses with lower MARS scores (21 and 20) as the cut-off for non-adherence showed lower levels of non-adherence (8.8% and 5.7%, respectively) and fewer statistically significant differences in patient characteristics between adherent and non-adherent patients. Differences in BMQ between adherent and non-adherent patients remained with both cut-offs except for BMQ-Concern and BMQ-Harm when a MARS score of 20 was used as the cut-off (data not shown).

## DISCUSSION

This study showed associations between patients' beliefs about stroke and medicines and self-rated non-adherence to drug treatment. Only 12.5% of patients were classified as non-adherent 3 months after stroke. Beliefs about medicines showed stronger associations to adherence compared to illness perceptions, and non-adherent patients scored lower on positive beliefs about medicines and higher on negative beliefs.

Because having a stroke is often a serious and frightening experience, a low level of non-adherence to preventive drugs is expected only 3 months after stroke. Among the minority of patients reporting non-adherent behaviour, we showed an association between personal beliefs and adherence relatively soon after stroke. This indicates that patients who self-reported non-adherence early were patients for whom non-adherence was based on personal beliefs in medication harm and low beliefs in personal need for drugs.

Validated questionnaires have been used to collect data on a rather large sample of patients. None of the questionnaires have been validated specifically for stroke, but both MARS and BMQ have been used in studies of a range of conditions that included stroke[9, 18, 19] and Brief IPQ has been tested in myocardial infarction and diabetes.[13] The study had a high power. The power calculation estimated that the questionnaire had to be sent to at least 650 patients. Because all hospitals were invited, and the number and size of volunteering hospitals were not known in advance, those volunteering made it possible to include more than 650 patients.

There is no gold standard method to measure adherence.[20] Self-reported adherence measures are sometimes said to overestimate adherence because of self-presentation and recall bias, but a metaanalysis has shown that this is not always the case.[20] Instructions in the questionnaire were formulated to encourage patients to answer truthfully and assured the patients that their answers would not affect future care. MARS has been used in many studies of several long-term illnesses, including chronic pain,[21] asthma,[7] secondary prevention of coronary heart disease,[9] and stroke.[19] The only other option for measuring adherence would have been prescription refill data, but because Swedish prescriptions generally cover a time period of 3 months, only patients who did not buy a drug at all within the 3 months of having their stroke (primary non-adherence) would be classified as non-adherent. The proportion of primary non-adherence has been shown to be low (4–11 %) for secondary prevention of stroke.[22] Questions on adherence were not directed toward specific drugs or treatments, and if patients were selectively adherent this was not captured. The cross-sectional design of this study made it impossible to draw conclusions about causality or to measure changes in behaviour.

In a previous study, non-adherence was found to be higher in non-responders compared to responders.[23] Because adherence was self-reported in this study, non-adherence could not be estimated for non-responders. However, according to data from the stroke register non-responders more often reported poor general health or depression, more often had had a previous stroke, and more often were living alone. There was a larger proportion non-adherent patients among those with a history of stroke compared to first-time strokes. There could also have been other differences between responders and non-responders that were not tested in this study that could have affected the results.

1  
2  
3 In a study from the UK on predictors of adherence to secondary preventive treatment after stroke,  
4 associations between BMQ-specific (*Necessity* and *Concern*) and adherence were tested. Statistically  
5 significant associations were found with subscale *Concern*.<sup>[19]</sup> A study on secondary prevention of  
6 coronary heart disease found adherence to be related to both BMQ subscales *Necessity* and  
7 *Concern*.<sup>[9]</sup> Several studies have also shown similar results with stronger associations between  
8 adherence behaviour and beliefs about medicines than with illness perceptions.<sup>[7-9]</sup> This is also in  
9 line with the extended self-regulatory model according to which illness perceptions could be directly  
10 related to adherence but also, and often stronger, indirectly through associations between illness  
11 perception and beliefs about medicines.<sup>[21]</sup> The full model has not been tested in this study. This  
12 study was performed in Sweden, and although different personal beliefs sometimes reflect cultural  
13 differences the associations found in this sample were consistent with results from studies in other  
14 countries.<sup>[8, 9, 24]</sup>

15  
16  
17  
18  
19 In this study MARS scores were dichotomized, but in some studies they have been used as a  
20 continuous variable. The chosen cut-off allowed adherent patients to answer “rarely” on two  
21 questions or “sometimes” on one, and this cut-off has been used in other studies.<sup>[25]</sup> Changing the  
22 cut-off from 22 to 21 or 20 decreased the number of patients classified as non-adherent but only  
23 marginally changed the associations between personal beliefs and self-rated adherence.

24  
25  
26 Self-rated non-adherence in this sample was quite low 3 months after stroke, but in other studies  
27 non-adherence has been shown to increase over time.<sup>[4]</sup> Declining adherence is, of course, a  
28 problem but secondary prevention is also important early after stroke.<sup>[26, 27]</sup> Because the results  
29 from this study and other studies showed associations between beliefs about medicines and  
30 adherence to treatment, it might be important to incorporate these questions into discussions with  
31 patients about preventing further illness, maybe even using questions from the BMQ. It seems  
32 important for clinical staff to try to assess patients’ views of medicines, not just informing patients  
33 about medicines or trying to convince patients to use medicines. Giving patients information and  
34 instructions is sometimes considered enough, but information is not the same as education. Patients’  
35 perceptions or behaviours are rarely discussed in clinical guidelines.

36  
37  
38  
39 In conclusion, although self-rated non-adherence 3 months after stroke was low, associations  
40 between patients’ beliefs about medicines and non-adherence were seen in this sample of Swedish  
41 stroke patients. Patients’ personal beliefs need to be considered when prescribing medicines or  
42 trying to improve patients’ use of medicines.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Acknowledgments:** The authors would like to thank all of the stroke patients who answered our  
4 questionnaire, and the Riks-Stroke contacts in all 25 hospitals that helped us with sending and  
5 collecting the questionnaires. The authors are also thankful to Riks-Stroke for providing the database  
6 and to Professor Rune Dahlqvist for his comments on the manuscript.  
7

8  
9 **Contributors:** All authors contributed to the article by participating in the design (MS, ME, ELG),  
10 acquisition of data (MS, ELG), analysis or interpretation of data (MS, ME, ELG), drafting the  
11 manuscript (MS, ELG) and revising it critically (MS, ME, ELG), and approving the final manuscript (MS,  
12 ME, ELG).  
13

14 **Competing interests:** None  
15

16 **Funding:** Riks-Stroke, the Swedish Stroke Register, is funded by the National Board of Health and  
17 Welfare and the Swedish Association of Local Authorities and Regions. For this study, the authors  
18 received grant support from Västerbotten County Council and the Northern Swedish Stroke Fund.  
19

20 **Data sharing statement:** No additional data are available.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




## REFERENCES

1. Socialstyrelsen. Nationella riktlinjer för strokesjukvård 2009 - Stöd för styrning och ledning. (National guidelines for stroke care 2009) (in Swedish). The Swedish National Board of Health and Welfare, Stockholm. Stockholm 2009.
2. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization 2003.
3. Robin DiMatteo MP, Giordani PJMA, Lepper HSP, et al. Patient Adherence and Medical Treatment Outcomes: A Meta-Analysis. *Med Care*. 2002;**40**:794-811.
4. Glader E-L, Sjölander M, Eriksson M, et al. Persistent Use of Secondary Preventive Drugs Declines Rapidly During the First 2 Years After Stroke. *Stroke*. 2010;**41**:397-401.
5. Jin J, Sklar GE, Oh VMS, et al. Factors affecting therapeutic compliance: A review from the patient's perspective *Therapeutics and Clinical Risk Management*. 2008;**4**:269-86.
6. Leventhal H, Diefenbach M, Leventhal E. Illness cognition: Using common sense to understand treatment adherence and affect cognition interactions. *Cognitive Therapy and Research*. 1992;**16**:143-63.
7. Horne R, Weinman J. Self-regulation and Self-management in Asthma: Exploring The Role of Illness Perceptions and Treatment Beliefs in Explaining Non-adherence to Preventer Medication. *Psychology & Health*. 2002;**17**:17-32.
8. Ross S, Walker A, MacLeod MJ. Patient compliance in hypertension: role of illness perceptions and treatment beliefs. *J Hum Hypertens*. 2004;**18**:607-13.
9. Byrne M, Walsh J, Murphy AW. Secondary prevention of coronary heart disease: Patient beliefs and health-related behaviour. *J Psychosom Res*. 2005;**58**:403-15.

- 1  
2  
3 10. Horne R. Beliefs and adherence to treatment: the challenge for research and clinical  
4 practice. In: Halligan P, Aylward M, ed. *The Power of Belief*. Oxford: Oxford University Press, 2006.  
5  
6  
7  
8 11. Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication  
9 adherence. *Cochrane Database of Systematic Reviews*. 2008:CD000011.  
10  
11  
12 12. Asplund K, Hulter Åsberg K, Appelros P, et al. The Riks-Stroke story: building a  
13 sustainable national register for quality assessment of stroke care. *International Journal of Stroke*.  
14 2011;**6**:99-108.  
15  
16  
17 13. Broadbent E, Petrie KJ, Main J, et al. The Brief Illness Perception Questionnaire. *J*  
18 *Psychosom Res*. 2006;**60**:631-7.  
19  
20  
21 14. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: The  
22 development and evaluation of a new method for assessing the cognitive representation of  
23 medication. *Psychology & Health*. 1999;**14**:1-24.  
24  
25  
26 15. Horne R, Frost S, Hankins M, et al. "In the eye of the beholder": pharmacy students  
27 have more positive perceptions of medicines than students of other disciplines. *International Journal*  
28 *of Pharmacy Practice*. 2001;**9**:85-9.  
29  
30  
31 16. Mahler C, Hermann K, Horne R, et al. Assessing reported adherence to  
32 pharmacological treatment recommendations. Translation and evaluation of the Medication  
33 Adherence Report Scale (MARS) in Germany. *J Eval Clin Pract*. 2010;**16**:574-9.  
34  
35  
36 17. Tavakol M, Dennick R. Making sense of Cronbach's alpha. *Int J Med Educ*. 2011;**2**:53-5.  
37  
38  
39 18. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in  
40 adherence to treatment in chronic physical illness. *J Psychosom Res*. 1999;**47**:555-67.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 19. O'Carroll R, Whittaker J, Hamilton B, et al. Predictors of Adherence to Secondary  
4 Preventive Medication in Stroke Patients. *Ann Behav Med.* 2011;**41**:383-90.  
5  
6  
7  
8 20. DiMatteo MR. Variations in Patients' Adherence to Medical Recommendations: A  
9 Quantitative Review of 50 Years of Research. *Med Care.* 2004;**42**:200-9.  
10  
11  
12  
13 21. Nicklas LB, Dunbar M, Wild M. Adherence to pharmacological treatment of non-  
14 malignant chronic pain: The role of illness perceptions and medication beliefs. *Psychology & Health.*  
15  
16 2010;**25**:601-15.  
17  
18  
19  
20 22. Sjölander M, Eriksson M, Glader E-L. Few sex differences in the use of drugs for  
21 secondary prevention after stroke: a nationwide observational study. *Pharmacoepidemiology and*  
22  
23 *Drug Safety.* 2012;**21**:911-9.  
24  
25  
26  
27  
28 23. Gadkari AS, Pedan A, Gowda N, et al. Survey Nonresponders to a Medication-beliefs  
29 Survey Have Worse Adherence and Persistence to Chronic Medications Compared With Survey  
30  
31 Responders. . *Medical Care* 2011;**49** 956-61.  
32  
33  
34  
35 24. Menckeberg TT, Bouvy ML, Bracke M, et al. Beliefs about medicines predict refill  
36 adherence to inhaled corticosteroids. *J Psychosom Res.* 2008;**64**:47-54.  
37  
38  
39  
40 25. Mårdby A-C, Åkerlind I, Jörgensen T. Beliefs about medicines and self-reported  
41 adherence among pharmacy clients. *Patient Educ Couns.* 2007;**69**:158-64.  
42  
43  
44  
45 26. Sanossian N, Ovbiagele B. The risk of stroke within a week of minor stroke or transient  
46 ischemic attack. *Expert Opinion on Pharmacotherapy.* 2008;**9**:2069-76.  
47  
48  
49  
50 27. Field T, Benavente O. Current Status of Antiplatelet Agents to Prevent Stroke. *Current*  
51  
52 *Neurology and Neuroscience Reports.* 2011;**11**:6-14.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Flowchart of hospitals and patients in the study  
209x297mm (300 x 300 DPI)

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-7
Bias	9	Describe any efforts to address potential sources of bias	5-7
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7
		(b) Describe any methods used to examine subgroups and interactions	-
		(c) Explain how missing data were addressed	6
		(d) If applicable, describe analytical methods taking account of sampling strategy	-
		(e) Describe any sensitivity analyses	6
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9
		(b) Give reasons for non-participation at each stage	9
		(c) Consider use of a flow diagram	9 (figure)
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9-11
		(b) Indicate number of participants with missing data for each variable of interest	(12)
Outcome data	15*	Report numbers of outcome events or summary measures	11
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11-12
		(b) Report category boundaries when continuous variables were categorized	7
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	12
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	13
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14
Generalisability	21	Discuss the generalisability (external validity) of the study results	14
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).



## Association between patients' beliefs about medicines and adherence to drug treatment after stroke

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003551.R1
Article Type:	Research
Date Submitted by the Author:	20-Aug-2013
Complete List of Authors:	Sjölander, Maria; Umeå University, Department of Pharmacology and Clinical Neuroscience; Umeå University, Department of Public Health and Clinical Medicine Eriksson, Marie; Umeå University, Department of Statistics Glader, Eva-Lotta; Umeå University, Department of Public Health and Clinical Medicine
<b>Primary Subject Heading</b>:	Pharmacology and therapeutics
Secondary Subject Heading:	Patient-centred medicine, Neurology, Cardiovascular medicine
Keywords:	STROKE MEDICINE, CLINICAL PHARMACOLOGY, PREVENTIVE MEDICINE, THERAPEUTICS

SCHOLARONE™  
Manuscripts

1  
2  
3 Title: Association between patients' beliefs about medicines and adherence to drug treatment after  
4 stroke  
5  
6  
7

8 Corresponding author:  
9

10 Maria Sjölander, MPH  
11

12 Department of Public Health and Clinical Medicine/Department of Pharmacology and Clinical  
13 Neuroscience  
14

15 Umeå University  
16

17 S-901 87 Umeå  
18

19 Sweden  
20

21 Telephone +46 90 7853904, Fax +46 90 120430  
22

23 [maria.sjolander@pharm.umu.se](mailto:maria.sjolander@pharm.umu.se)  
24  
25  
26  
27

28 Marie Eriksson, PhD  
29

30 Department of Statistics, Umeå School of Business and Economics  
31

32 Umeå University  
33

34 Umeå, Sweden  
35  
36  
37

38 Eva-Lotta Glader, MD  
39

40 Department of Public Health and Clinical Medicine  
41

42 Umeå University  
43

44 Umeå, Sweden  
45  
46  
47

48 Keywords: stroke prevention, medication adherence, medication beliefs, illness perception,  
49

50 Word count: 3246  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## ABSTRACT

Objectives: Adherence to preventive drug treatment is a clinical problem and we hypothesized that patients' beliefs about medicines and stroke are associated with adherence. The objective was to examine associations between stroke patients' beliefs about stroke and drug treatment and their adherence to drug treatment.

Design: Cross-sectional questionnaire survey.

Setting: Stroke patients from 25 Swedish hospitals were included.

Measurements: Questionnaires were sent to 989 patients to assess their perceptions about stroke (Brief Illness Perception Questionnaire, Brief IPQ), beliefs about medicines (Beliefs about Medicines Questionnaires, BMQ), and adherence to treatment (Medication Adherence Report Scale, MARS) 3 months after stroke onset. Only patients living at home were included in the analysis. The primary outcome was self reported adherence as measured on MARS. MARS scores were dichotomized into adherent/non-adherent. Background and clinical data from the Swedish Stroke register were included.

Results: Eight hundred eleven patients were still living at home and 595 answered the questionnaire. Complete MARS data was available for 578 patients, and 72 (12.5 %) of these were classified as non-adherent. Non-adherent patients scored lower on positive beliefs as measured on BMQ-Necessity (Odds ratio (OR) = 0.90, 95% CI 0.83–0.98) and BMQ-Benefit (OR = 0.77, 95% CI 0.68–0.87), and higher on negative beliefs as measured on BMQ-Concern (OR = 1.12, 95% CI 1.05–1.21), BMQ-Overuse (OR = 1.29, 95% CI 1.14–1.45), and BMQ-Harm (OR = 1.12, 95% CI 1.01–1.24). The Brief IPQ showed that non-adherent patients believed their current treatment to be less useful ( $p = 0.001$ ).

Conclusions: This study showed associations between Swedish stroke patients' beliefs about medicines and adherence. Positive beliefs were less common and negative more common among non-adherent. To improve adherence, patients' beliefs about medicines should be considered.

## ARTICEL SUMMARY

### Article focus

- Poor patient adherence to secondary preventive drug treatment after stroke is a clinical problem.
- The objectives of this study were to examine stroke patients' beliefs about stroke and drug treatment after stroke, and to investigate if these beliefs are associated with patients' adherence to drug treatment after stroke

### Key messages

- There were associations between stroke patients' beliefs about medicines and non-adherence.
- Non-adherent patients scored lower on positive beliefs about medicines and higher on negative beliefs.
- Patients' personal beliefs need to be considered when prescribing medicines or trying to improve patients' use of medicines.

### Strengths and limitations of this study

- Validated questionnaires have been used to collect data on a large sample of patients.
- Although only a minority of patients reported non-adherent behaviour, associations between beliefs and adherence were statistically significant.
- The cross-sectional design made it impossible to draw conclusions about causality.

## INTRODUCTION

Stroke is the third leading cause of death in Sweden and causes great suffering among survivors and claims vast amounts of resources. Preventive treatment is of great importance, and secondary preventive drug treatment is recommended to most stroke patients to prevent recurrent strokes.[1] Patients' adherence to prescribed long-term and/or preventive treatment has, however, been shown to be low,[2] and this results in poor treatment outcomes in non-adherent patients.[3] A previous study on Swedish stroke patients showed that between 25% and 50% of patients, depending on the type of drug, discontinue secondary preventive drug treatment within 2 years after a stroke.[4]

Many factors have been tested for predictability of adherence.[5] Some treatment or healthcare related factors, such as simplified dosage regimens or satisfaction with health care, have been found to associate with a higher degree of adherence. It has been more difficult to find consistent associations between demographics and psycho-social factors and adherence, possibly because of interactions between factors.[5]

Several theoretical models have been developed to explain associations between psychological factors and health-related behaviour in general and adherence behaviour specifically. The model most often discussed in relation to patient adherence is Howard Leventhal's self-regulatory model (SRM).[6] According to an extended version of the SRM, both beliefs about medicines and illness perceptions are related to adherence.[7-9] Non-adherence is often assumed to be involuntary or unintentional – that patients forget, are unable to handle, or cannot afford the drug – but non-adherence is also quite often based on a decision, sometimes called 'intentional non-adherence'.[10] Intentional non-adherence is based on personal beliefs of possible risks from the disease itself, possible risks from the treatment, and with perceived need of the treatment.

Interventions to improve patients' long-term use of drugs are, although often complex, not very effective.[11] Preventive drug therapy after stroke is both a long-term and asymptomatic treatment, and to improve adherence it might be important to consider patients' beliefs about medicines and stroke. We hypothesized that patients' beliefs about medicines and stroke are associated with drug adherence among stroke patients. The objectives of this study were to examine stroke patients' beliefs about stroke and drug treatment after stroke, and to investigate if these beliefs are associated with patients' adherence to drug treatment after stroke.

## METHODS

In this cross-sectional study, questionnaire data on attitudes and beliefs about stroke and medicines has been merged with clinical data from the Swedish stroke register (Riks-Stroke). The study questionnaire and the follow-up questionnaire from the stroke register were sent to the patients 3 months after stroke onset.

The participants in this study were all stroke patients who were registered in Riks-Stroke from December 2011 to March 2012. Riks-Stroke was established in 1994, and since 1998 all hospitals that admit acute stroke patients report to the register.[12] In 2011, the register was estimated to cover 90.5% of all stroke cases in Sweden. All 74 hospitals participating in the stroke register were invited to participate and 25 of the hospitals volunteered. The participating hospitals are situated in 15 of the 21 counties/regions in Sweden and represent both rural and urban areas. University hospitals (n = 4), large non-university hospitals (n = 11), and community hospitals (n = 10) were included.

Only patients who, according to the stroke register, were living at home 3 months after they had suffered their stroke were included in the study. For other patients, such as patients living in institutions, non-individual routines were assumed to have too much of an effect on patient adherence.

Background information on the patient and information about the stroke event was obtained from Riks-Stroke through the patient's personal identification number. Intracerebral haemorrhages, cerebral infarctions, and strokes not specified as haemorrhage or infarction (diagnosis codes ICD-10: I61, I63, and I64) are included in Riks-Stroke. The register contains patient-related information and data about care both from the acute phase of the stroke and from a 3-month follow-up questionnaire.

Data on patients' beliefs about stroke, medicines, and patient adherence to treatment were collected through a questionnaire consisting of 35 questions with answers on Likert-type scales. The following three validated questionnaires were used in our study: the Brief Illness Perception Questionnaire (Brief IPQ), the Beliefs about Medicines Questionnaires (BMQ), and the Medication Adherence Report Scale (MARS).

The Brief IPQ consists of nine questions aimed at examining patients' cognitive and emotional ideas about their disease.[13] The Brief IPQ has been tested in several illness groups and shows reliability and validity.[13] For this study, questions have been modified to be more specific to stroke (e.g. replacing the word "illness" with "stroke"), and the face validity of the translation to Swedish was tested on a sample of Swedish stroke patients. The answers to the first eight questions in the Brief IPQ that were used in this study (Table 1) were rated on a scale from 0 to 10. The last question in the Brief IPQ is open-ended to assess what patients believe are the three most important causes of their stroke, but this question would have required qualitative analysis and, therefore, was not used.

**Table 1** Back-translation of the questions in the modified Brief Illness Perception Questionnaire

Question Nr	Back-translation of the questions in the modified Brief Illness Perception Questionnaire
1	How much does your stroke affect your life?
2	How long do you think your stroke will affect you?

3	How much control do you feel you have over your stroke/stroke symptoms?
4	How much do you think your treatment can prevent another stroke?
5	How much do you experience symptoms from your stroke?
6	How concerned are you about having another stroke?
7	How much do you think you know about stroke?
8	How much does your stroke affect you emotionally? (e.g. does it make you angry, scared, upset or depressed?)

The BMQ has been developed to assess personal beliefs about medicines.[14, 15] BMQ-Specific assesses patients' beliefs about drugs prescribed for their personal use, and BMQ-General assesses beliefs about medicines in general. The BMQ-Specific has two subscales (*Necessity* and *Concern*) with five questions each, and the BMQ-General has three subscales (*Harm*, *Overuse* and *Benefit*) with four questions each. Representations of the different BMQ subscales are presented in Table 2. Answers to all 22 questions were scored on a 5-point Likert scale (1 = strongly disagree, 2 = disagree, 3 = uncertain, 4 = agree, 5 = strongly agree) and a total score per BMQ scale was calculated. For individuals with one or more answers missing, the total scores of the corresponding BMQ subscales were excluded.

**Table 2** Representations of the different questionnaire subscales used to assess patients' beliefs about medicines.

BMQ-Subscales	Representation of personal beliefs
BMQ-Specific	
- Necessity	perceived personal need for medicine to maintain or improve own health
- Concern	perceived concern about negative effects of their own use of medicines
BMQ-General	
- Harm	perceived harmful nature of medicines in general
- Overuse	perceived notion that doctors overuse or put too much trust in medicines
- Benefit	perceived potential benefits of medicines in general

Self-rated non-adherence to treatment was the main outcome of this study, and this was assessed using the 5-item version of the MARS.[16] MARS and BMQ have previously been translated into Swedish with back-translation approved by the developer of the original questionnaires. The MARS-5 consists of five general statements about non-adherent behaviour (*I forget to take my medicines, I alter the dose of my medicines, I stop taking my medicines for a while, I decide to miss out a dose, I take less than instructed*) answered on a 5-point Likert scale (1 = *always*, 2 = *often*, 3 = *sometimes*, 4 = *rarely*, 5 = *never*). The outcome variable was calculated as the total score on the MARS-5 and a score of 5–22 was considered non-adherent and a score of 23–25 was considered adherent. Sensitivity analyses were performed with MARS scores 21 and 20 as the cut-off for non-adherence. Individuals missing one or more answers on the MARS were excluded from the analysis because their total MARS score would not be comparable with the rest of the study population.

#### Power calculation

1  
2  
3 The main hypothesis of the study was that there is a difference in BMQ between adherent and non-  
4 adherent patients as defined by their MARS score. Including 388 individuals, of whom approximately  
5 half are adherent, gives the study 80% power to detect a difference of 0.2 (BMQ) between adherent  
6 and non-adherent patients if the standard deviation for the difference is 0.7. This calculation is based  
7 on a 2-tailed t-test and a significance level of 0.05. To compensate for an ordinal response variable  
8 (BMQ) and a possible non-response (up to 40%), at least 650 individuals needed to be sent a  
9 questionnaire.  
10

### 11 12 **Statistical analyses**

13  
14 Differences in background and medical factors were tested using the Chi-squared test. The factors  
15 tested were age, sex, type of stroke, low level of consciousness at admission to hospital, history of  
16 stroke, and stroke unit treatment, and the factors from the 3 month follow-up were living alone,  
17 smoking, self-reported bad general health, self-reported depression, whether dependent on help  
18 and/or support from relatives, having had a return visit to a doctor and/or nurse, and self-reported  
19 difficulties with memory. Age was coded as <75 years or ≥75 years, sex as “Man” or “Woman”, type  
20 of stroke as “Haemorrhage” or “Other”, and difficulties with memory as “Never/almost never”,  
21 “Sometimes”, and “Often/constantly”. Answers to all other factors were coded “No” or “Yes”.  
22 Factors with a statistically significant difference ( $p < 0.05$ ) between adherent and non-adherent  
23 patients were included in multivariable analyses.  
24

25  
26 The results for individual Brief IPQ questions and BMQ subscales were calculated as medians and  
27 inter quartile ranges (IQR). Mann-Whitney U tests were used to test differences between adherent  
28 and non-adherent patients in illness perceptions (individual items in the Brief IPQ) and beliefs about  
29 medicines (BMQ subscales).  
30

31  
32 Besides descriptive analyses with group comparisons, the statistical analysis also included  
33 multivariable methods to control for several factors simultaneously. The outcome measure (self  
34 reported adherence as measured with MARS) was dichotomised, and logistic regression was used for  
35 multivariable analyses. For categorical co-variables, “<75 years”, “Man”, “Haemorrhage”,  
36 “Never/almost never” having difficulties with memory, and “No” were chosen as reference  
37 categories. After checking the linearity assumption, the Brief IPQ scores and the BMQ scores were  
38 included as continuous covariates in the logistic regression models. Results are presented as odds  
39 ratios (OR) with 95% confidence intervals (CI). Only one BMQ scale at a time was included in the  
40 regression models because the objective was to study associations between different beliefs about  
41 medicines and adherence. Spearman’s correlation coefficient was used to test for correlations  
42 between the different BMQ subscales.  
43

44  
45 An analysis of non-responders was performed using data from the stroke register. Non-responders  
46 were compared by Chi-squared test to responders in regards to the same background and medical  
47 factors as described above.  
48

49  
50 Internal consistency within BMQ subscales and MARS was measured with Cronbach’s alpha. A high  
51 value indicates high intercorrelation between items in a subscale, and values over 0.7 are considered  
52 acceptable.[17]  
53

54  
55 Statistical analyses were performed using IBM SPSS Statistics version 21.0  
56  
57  
58  
59  
60

**Ethics**


This study was approved by the Ethical Review Board at Umeå University on January 17, 2012, Reg. No 2011-375-31M.

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## RESULTS

The study questionnaire was sent to 989 patients who were discharged from hospital to their own homes. Of these, 811 were living at home 3 months after their stroke and were included for further analysis. Out of these 811, 595 (73.4 %) responded to the questionnaire. Figure 1 shows a flowchart of hospitals and patients in the study.



**Figure 1** Flowchart of hospitals and patients in the study

Five hundred seventy-eight patients had complete answers to the adherence questions (MARS), and 72 (12.5 %) of these were classified as non-adherent. The proportion of patients who self-reported non-adherent behaviour (the answers “sometimes”, “often”, and “always”) on any of the MARS statements were 9.7% for “I forget to take my medicines”, 12.8% for “I alter the dose of my medicines”, 2.2% for “I stop taking my medicines for a while”, 8.4% for “I decide to miss out on a dose”, and 4.5% for “I take less than instructed”.

Differences in background and medical factors between adherent and non-adherent patients are presented in Table 3. Non-adherent patients were more often men, not treated in stroke units, dependent on the help and support from relatives, had a history of stroke, and more often self-reported memory difficulties compared to adherent patients.



**Table 3** Patient characteristics by level of adherence. Chi-squared test of differences between non-adherent and adherent patients.

<i>Variable/Characteristic</i>	<i>Non-adherent (n = 72)</i>	<i>Adherent (n = 506)</i>	<i>p</i>
Age, n (%)			0.341
- < 75 years	38 (11.3)	297 (88.7)	
- ≥ 75 years	34 (14.0)	209 (86.0)	
Sex, n (%)			0.042
- Men	51 (14.7)	295 (85.3)	
- Women	21 (9.1)	211 (90.9)	
Type of stroke, n (%)			0.325
- Haemorrhage	3 (7.5)	37 (92.5)	
- Other (ICD10 I63 + I64)	69 (12.8)	469 (87.2)	
Low level of consciousness at admission, n (%)			0.770
- No	68 (12.4)	480 (87.6)	
- Yes (Drowsy or unconscious)	4 (14.3)	24 (85.7)	
History of stroke, n (%)			0.010
- No	54 (11.0)	437 (89.0)	
- Yes	18 (20.9)	68 (79.1)	
Treated in stroke unit, n (%)			0.016
- No	6 (30.0)	14 (70.0)	
- Yes	66 (11.8)	491 (88.2)	
<b>3 months follow-up</b>			
Living alone, n (%)			0.241
- No	45 (11.2)	357 (88.8)	
- Yes	25 (14.7)	145 (85.3)	
Smoking, n (%)			0.303
- No	64 (12.1)	463 (87.9)	
- Yes	8 (17.4)	38 (82.6)	
Self-reported bad general health, n (%)			0.210
- No	56 (11.6)	426 (88.4)	
- Yes	14 (16.5)	71 (83.5)	
Self-reported depression, n (%)			0.147
- No	51 (11.4)	396 (88.6)	
- Yes	18 (16.5)	91 (83.5)	
Dependent on help/support from relatives, n (%)			0.015
- No	26 (9.0)	263 (91.0)	
- Yes	43 (15.8)	230 (84.2)	
Return visit, n (%)			0.521
- No	7 (9.9)	64 (90.1)	
- Yes	60 (12.5)	419 (87.5)	
Difficulties with memory, n (%)			0.014
- Never or almost never	25 (11.1)	200 (88.9)	
- Sometimes	29 (10.7)	241 (89.3)	
- Often or constantly	17 (23.0)	57 (77.0)	

Internal consistency for BMQ subscales and MARS, measured by Cronbach's alpha, showed highest values for the BMQ-Specific scales (Table 4).

**Table 4** Descriptive of questionnaire scales used.

<i>Scale</i>	<i>Number of items in scale</i>	<i>Range of scores</i>	<i>Cronbach's alpha</i>
BMQ-Specific			
- Necessity	5	5-25	0.823
- Concern	5	5-25	0.818
BMQ-General			
- Overuse	4	4-20	0.684
- Harm	4	4-20	0.647
- Benefit	4	4-20	0.697
MARS	5	5-25	0.723

Results from question 4 on the modified Brief IPQ "How much do you think your current treatment can prevent another stroke?" showed that non-adherent patients believed their current treatment to be less useful (median = 5 (IQR 3–7)) compared to adherent patients (median = 7 (IQR 5–8)) and this difference was statistically significant ( $p = 0.001$ ). No other Brief IPQ-question showed a significant difference between adherent and non-adherent patients.

Results for total BMQ scale scores are presented and compared in Table 5. All BMQ subscales except *Necessity* showed statistically significant differences between adherent and non-adherent patients in the univariate analysis.

**Table 5** Scale score medians and inter quartile ranges (IQR) for the scales used to assess patients' beliefs about medicines (BMQ), comparing non-adherent with adherent patients.

<i>Variable</i>	<i>Valid cases (n = 578)</i>	<i>Scale score median (IQR)</i>		<i>Mann-Whitney U test (p-value)</i>	<i>Adjusted with multivariable logistic regression* OR for a one-unit increase (95% CI)</i>
		<i>Non-Adherent (n = 72)</i>	<i>Adherent (n = 506)</i>		
BMQ-Specific					
- Necessity	558	18 (16-20)	19 (17-21)	0.079	0.90 (0.83-0.98)
- Concern	552	14 (11-17)	12 (9-15)	<0.001	1.12 (1.05-1.21)
BMQ-General					
- Overuse	556	13 (11-14)	11 (10-13)	<0.001	1.29 (1.14-1.45)
- Harm	544	11 (9-12.25)	10 (8-12)	0.038	1.12 (1.01-1.24)
- Benefit	560	16 (14-16)	16 (15-18)	<0.001	0.77 (0.68-0.87)

\* Adjusted for age, sex, history of stroke, if treated in stroke unit, dependent on help/support from relatives, difficulties with memory, Brief IPQ – question 4, and respective BMQ subscale.

The multivariable logistic regression models showed associations between all five subscales on beliefs about medicines and non-adherence to treatment. Non-adherent stroke patients had lower

scores on the positive statements about medicines as measured on both BMQ subscales *Necessity* (OR = 0.90, 95% CI 0.83–0.98) and *Benefit* (OR = 0.77, 95% CI 0.68–0.87). Non-adherent patients also scored higher on the negative beliefs as measured on BMQ subscales *Concern* (OR = 1.12, 95% CI 1.05–1.21), *Harm* (OR = 1.12, 95% CI 1.01–1.24), and *Overuse* (OR = 1.29, 95% CI 1.14–1.45). Correlations between the different BMQ subscales were statistically significant except between *Necessity* and *Concern* (Table 6).

**Table 6** Correlation matrix for different scales used to test beliefs about medicines. Spearman's correlation coefficient (p-value).

	BMQ- Necessity	BMQ- Concern	BMQ- Overuse	BMQ- Harm	BMQ- Benefit
BMQ- Necessity	1				
BMQ- Concern	-0.075 (0.080)	1			
BMQ- Overuse	-0.226 (<0.001)	0.434 (<0.001)	1		
BMQ- Harm	-0.185 (<0.001)	0.444 (<0.001)	0.558 (<0.001)	1	
BMQ- Benefit	0.315 (<0.001)	-0.287 (<0.001)	-0.322 (<0.001)	-0.362 (<0.001)	1

Out of the 356 non-responders, 216 were still living at home 3 months after the stroke onset. Patients who responded to the questionnaire were compared to non-responders in terms of background and medical factors (the same factors were tested as in Table 3). The results of this analysis showed that non-responders more often had a history of stroke ( $p = 0.018$ ), self-reported bad general health ( $p = 0.001$ ), depression ( $p = 0.012$ ), were living alone ( $p = <0.001$ ), and were smoking ( $p = 0.046$ ). Non-responders had been treated in university hospitals ( $n = 27$ ), large non-university hospitals ( $n = 140$ ), and community hospitals ( $n = 49$ ).

The variables from Riks-Stroke with the highest numbers of missing data were, for responders ( $n = 595$ ), return visits ( $n = 28$ ) and self-reported depression ( $n = 22$ ), and for non-responders ( $n = 216$ ), return visits ( $n = 18$ ) and self-reported depression ( $n = 14$ ).

Sensitivity analyses with lower MARS scores (21 and 20) as the cut-off for non-adherence showed lower levels of non-adherence (8.8% and 5.7%, respectively) and fewer statistically significant differences in patient characteristics between adherent and non-adherent patients. Differences in BMQ between adherent and non-adherent patients remained with both cut-offs except for BMQ-Concern and BMQ-Harm when a MARS score of 20 was used as the cut-off (data not shown).

## DISCUSSION

This study showed associations between patients' beliefs about stroke and medicines and self-rated non-adherence to drug treatment. Only 12.5% of patients were classified as non-adherent 3 months after stroke. Beliefs about medicines showed stronger associations to adherence compared to illness perceptions, and non-adherent patients scored lower on positive beliefs about medicines and higher on negative beliefs.

Because having a stroke is often a serious and frightening experience, a low level of non-adherence to preventive drugs is expected only 3 months after stroke. Among the minority of patients reporting non-adherent behaviour, we showed an association between personal beliefs and adherence relatively soon after stroke. This indicates that patients who self-reported non-adherence early were patients for whom non-adherence was based on personal beliefs in medication harm and low beliefs in personal need for drugs.

Validated questionnaires have been used to collect data on a rather large sample of patients. None of the questionnaires have been validated specifically for stroke, but both MARS and BMQ have been used in studies of a range of conditions that included stroke[9, 18, 19] and Brief IPQ has been tested in myocardial infarction and diabetes.[13] The study had a high power. The power calculation estimated that the questionnaire had to be sent to at least 650 patients. Because all hospitals were invited, and the number and size of volunteering hospitals were not known in advance, those volunteering made it possible to include more than 650 patients.

There is no gold standard method to measure adherence.[20] Self-reported adherence measures are sometimes said to overestimate adherence because of self-presentation and recall bias, but a metaanalysis has shown that this is not always the case.[20] Instructions in the questionnaire were formulated to encourage patients to answer truthfully and assured the patients that their answers would not affect future care. MARS has been used in many studies of several long-term illnesses, including chronic pain,[21] asthma,[7] secondary prevention of coronary heart disease,[9] and stroke.[19] The only other option for measuring adherence would have been prescription refill data, but because Swedish prescriptions generally cover a time period of 3 months, only patients who did not buy a drug at all within the 3 months of having their stroke (primary non-adherence) would be classified as non-adherent. The proportion of primary non-adherence has been shown to be low (4–11 %) for secondary prevention of stroke.[22] Questions on adherence were not directed toward specific drugs or treatments, and if patients were selectively adherent this was not captured. The cross-sectional design of this study made it impossible to draw conclusions about causality or to measure changes in behaviour.

In a previous study, non-adherence was found to be higher in non-responders compared to responders.[23] Because adherence was self-reported in this study, non-adherence could not be estimated for non-responders. However, according to data from the stroke register non-responders more often reported poor general health or depression, more often had had a previous stroke, and more often were living alone. There was a larger proportion non-adherent patients among those with a history of stroke compared to first-time strokes. Patients with a history of stroke might have different opinions or perceptions about stroke at this early point after stroke (3 months). With the larger proportion of patients with a previous stroke among non-responders, this could have affected

1  
2  
3 the results on illness perceptions. There could also have been other differences between responders  
4 and non-responders that were not tested in this study that could have affected the results.  
5

6  
7 In a study from the UK on predictors of adherence to secondary preventive treatment after stroke,  
8 associations between BMQ-specific (*Necessity* and *Concern*) and adherence were tested. Statistically  
9 significant associations were found with subscale *Concern*.<sup>[19]</sup> A study on secondary prevention of  
10 coronary heart disease found adherence to be related to both BMQ subscales *Necessity* and  
11 *Concern*.<sup>[9]</sup> Several studies have also shown similar results with stronger associations between  
12 adherence behaviour and beliefs about medicines than with illness perceptions.<sup>[7-9]</sup> This is also in  
13 line with the extended self-regulatory model according to which illness perceptions could be directly  
14 related to adherence but also, and often stronger, indirectly through associations between illness  
15 perception and beliefs about medicines.<sup>[21]</sup> The full model has not been tested in this study. This  
16 study was performed in Sweden, and although different personal beliefs sometimes reflect cultural  
17 differences the associations found in this sample were consistent with results from studies in other  
18 countries.<sup>[8, 9, 24]</sup>  
19  
20

21  
22 In this study MARS scores were dichotomized, but in some studies they have been used as a  
23 continuous variable. The chosen cut-off allowed adherent patients to answer “rarely” on two  
24 questions or “sometimes” on one, and this cut-off has been used in other studies.<sup>[25]</sup> Changing the  
25 cut-off from 22 to 21 or 20 decreased the number of patients classified as non-adherent but only  
26 marginally changed the associations between personal beliefs and self-rated adherence.  
27  
28

29  
30 Self-rated non-adherence in this sample was quite low 3 months after stroke, but in other studies  
31 non-adherence has been shown to increase over time.<sup>[4]</sup> Declining adherence is, of course, a  
32 problem but secondary prevention is also important early after stroke.<sup>[26, 27]</sup> Because the results  
33 from this study and other studies showed associations between beliefs about medicines and  
34 adherence to treatment, it might be important to incorporate these questions into discussions with  
35 patients about preventing further illness. Clinical staff should try to assess patients’ views of  
36 medicines, not just informing patients about medicines or trying to convince patients to use  
37 medicines. Giving patients information and instructions is sometimes considered enough, but  
38 information is not the same as education. Patients with negative beliefs about medicines need to be  
39 identified, and questions from the BMQ could be used for this. Because preventive drugs are  
40 important early after stroke, it is important to identify these patients early. Patients with a history of  
41 stroke or patients who have used the drugs for other reasons before stroke could be more inclined to  
42 have opinions about stroke and medicines already during hospital stay. However, most patients  
43 could briefly, already at discharge from hospital, be asked about their opinion about using preventive  
44 drugs. Most interventions that have shown effect on patient adherence to long-term treatments are  
45 complex and include combinations of several steps e.g. information, self-monitoring, counselling,  
46 supportive care.<sup>[11]</sup> These more complex interventions are likely more suitable for follow-up visits  
47 to hospitals or primary care visits, possibly led by specially trained nurses or trained clinical  
48 pharmacists, then for the acute inpatient phase. Patients’ perceptions or behaviours are rarely  
49 discussed in clinical guidelines.  
50  
51  
52  
53  
54

55  
56 In conclusion, although self-rated non-adherence 3 months after stroke was low, associations  
57 between patients’ beliefs about medicines and non-adherence were seen in this sample of Swedish  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

stroke patients. Patients’ personal beliefs need to be considered when prescribing medicines or trying to improve patients’ use of medicines.

For peer review only

1  
2  
3 **Acknowledgments:** The authors would like to thank all of the stroke patients who answered our  
4 questionnaire, and the Riks-Stroke contacts in all 25 hospitals that helped us with sending and  
5 collecting the questionnaires. The authors are also thankful to Riks-Stroke for providing the database  
6 and to Professor Rune Dahlqvist for his comments on the manuscript.  
7

8  
9 **Contributors:** All authors contributed to the article by participating in the design (MS, ME, ELG),  
10 acquisition of data (MS, ELG), analysis or interpretation of data (MS, ME, ELG), drafting the  
11 manuscript (MS, ELG) and revising it critically (MS, ME, ELG), and approving the final manuscript (MS,  
12 ME, ELG).  
13

14 **Competing interests:** None  
15

16 **Funding:** Riks-Stroke, the Swedish Stroke Register, is funded by the National Board of Health and  
17 Welfare and the Swedish Association of Local Authorities and Regions. For this study, the authors  
18 received grant support from Västerbotten County Council and the Northern Swedish Stroke Fund.  
19

20 **Data sharing statement:** No additional data are available.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## REFERENCES


1. Socialstyrelsen. Nationella riktlinjer för strokesjukvård 2009 - Stöd för styrning och ledning. (National guidelines for stroke care 2009) (in Swedish). The Swedish National Board of Health and Welfare, Stockholm. Stockholm 2009.
2. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization 2003.
3. Robin DiMatteo MP, Giordani PJMA, Lepper HSP, et al. Patient Adherence and Medical Treatment Outcomes: A Meta-Analysis. *Med Care*. 2002;**40**:794-811.
4. Glader E-L, Sjölander M, Eriksson M, et al. Persistent Use of Secondary Preventive Drugs Declines Rapidly During the First 2 Years After Stroke. *Stroke*. 2010;**41**:397-401.
5. Jin J, Sklar GE, Oh VMS, et al. Factors affecting therapeutic compliance: A review from the patient's perspective *Therapeutics and Clinical Risk Management*. 2008;**4**:269-86.
6. Leventhal H, Diefenbach M, Leventhal E. Illness cognition: Using common sense to understand treatment adherence and affect cognition interactions. *Cognitive Therapy and Research*. 1992;**16**:143-63.
7. Horne R, Weinman J. Self-regulation and Self-management in Asthma: Exploring The Role of Illness Perceptions and Treatment Beliefs in Explaining Non-adherence to Preventer Medication. *Psychology & Health*. 2002;**17**:17-32.
8. Ross S, Walker A, MacLeod MJ. Patient compliance in hypertension: role of illness perceptions and treatment beliefs. *J Hum Hypertens*. 2004;**18**:607-13.
9. Byrne M, Walsh J, Murphy AW. Secondary prevention of coronary heart disease: Patient beliefs and health-related behaviour. *J Psychosom Res*. 2005;**58**:403-15.



10. Horne R. Beliefs and adherence to treatment: the challenge for research and clinical practice. In: Halligan P, Aylward M, ed. *The Power of Belief*. Oxford: Oxford University Press, 2006.
11. Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. *Cochrane Database of Systematic Reviews*. 2008:CD000011.
12. Asplund K, Hulter Åsberg K, Appelros P, et al. The Riks-Stroke story: building a sustainable national register for quality assessment of stroke care. *International Journal of Stroke*. 2011;**6**:99-108.
13. Broadbent E, Petrie KJ, Main J, et al. The Brief Illness Perception Questionnaire. *J Psychosom Res*. 2006;**60**:631-7.
14. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication. *Psychology & Health*. 1999;**14**:1-24.
15. Horne R, Frost S, Hankins M, et al. "In the eye of the beholder": pharmacy students have more positive perceptions of medicines than students of other disciplines. *International Journal of Pharmacy Practice*. 2001;**9**:85-9.
16. Mahler C, Hermann K, Horne R, et al. Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the Medication Adherence Report Scale (MARS) in Germany. *J Eval Clin Pract*. 2010;**16**:574-9.
17. Tavakol M, Dennick R. Making sense of Cronbach's alpha. *Int J Med Educ*. 2011;**2**:53-5.
18. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. *J Psychosom Res*. 1999;**47**:555-67.

- 1  
2  
3 19. O'Carroll R, Whittaker J, Hamilton B, et al. Predictors of Adherence to Secondary  
4 Preventive Medication in Stroke Patients. *Ann Behav Med.* 2011;**41**:383-90.  
5  
6  
7  
8 20. DiMatteo MR. Variations in Patients' Adherence to Medical Recommendations: A  
9 Quantitative Review of 50 Years of Research. *Med Care.* 2004;**42**:200-9.  
10  
11  
12  
13 21. Nicklas LB, Dunbar M, Wild M. Adherence to pharmacological treatment of non-  
14 malignant chronic pain: The role of illness perceptions and medication beliefs. *Psychology & Health.*  
15  
16  
17 2010;**25**:601-15.  
18  
19  
20  
21 22. Sjölander M, Eriksson M, Glader E-L. Few sex differences in the use of drugs for  
22 secondary prevention after stroke: a nationwide observational study. *Pharmacoepidemiology and*  
23  
24  
25  
26  
27  
28 23. Gadkari AS, Pedan A, Gowda N, et al. Survey Nonresponders to a Medication-beliefs  
29 Survey Have Worse Adherence and Persistence to Chronic Medications Compared With Survey  
30  
31  
32  
33  
34  
35  
36 24. Menckeberg TT, Bouvy ML, Bracke M, et al. Beliefs about medicines predict refill  
37 adherence to inhaled corticosteroids. *J Psychosom Res.* 2008;**64**:47-54.  
38  
39  
40  
41 25. Mårdby A-C, Åkerlind I, Jörgensen T. Beliefs about medicines and self-reported  
42 adherence among pharmacy clients. *Patient Educ Couns.* 2007;**69**:158-64.  
43  
44  
45  
46 26. Sanossian N, Ovbiagele B. The risk of stroke within a week of minor stroke or transient  
47 ischemic attack. *Expert Opinion on Pharmacotherapy.* 2008;**9**:2069-76.  
48  
49  
50  
51 27. Field T, Benavente O. Current Status of Antiplatelet Agents to Prevent Stroke. *Current*  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Flowchart of hospitals and patients in the study  
209x297mm (300 x 300 DPI)

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-7
Bias	9	Describe any efforts to address potential sources of bias	5-7
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7
		(b) Describe any methods used to examine subgroups and interactions	-
		(c) Explain how missing data were addressed	6
		(d) If applicable, describe analytical methods taking account of sampling strategy	-
		(e) Describe any sensitivity analyses	6
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9
		(b) Give reasons for non-participation at each stage	9
		(c) Consider use of a flow diagram	9 (figure)
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9-11
		(b) Indicate number of participants with missing data for each variable of interest	(12)
Outcome data	15*	Report numbers of outcome events or summary measures	11
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11-12
		(b) Report category boundaries when continuous variables were categorized	7
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	12
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	13
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14
Generalisability	21	Discuss the generalisability (external validity) of the study results	14
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

1  
2  
3 Title: Association between patients' beliefs about medicines and adherence to drug treatment after  
4 stroke  
5  
6  
7

8 Corresponding author:  
9

10 Maria Sjölander, MPH  
11

12 Department of Public Health and Clinical Medicine/Department of Pharmacology and Clinical  
13 Neuroscience  
14

15 Umeå University  
16

17 S-901 87 Umeå  
18

19 Sweden  
20

21 Telephone +46 90 7853904, Fax +46 90 120430  
22

23 [maria.sjolander@pharm.umu.se](mailto:maria.sjolander@pharm.umu.se)  
24  
25  
26  
27

28 Marie Eriksson, PhD  
29

30 Department of Statistics, Umeå School of Business and Economics  
31

32 Umeå University  
33

34 Umeå, Sweden  
35  
36  
37

38 Eva-Lotta Glader, MD  
39

40 Department of Public Health and Clinical Medicine  
41

42 Umeå University  
43

44 Umeå, Sweden  
45  
46  
47

48 Keywords: stroke prevention, medication adherence, medication beliefs, illness perception,  
49

50 Word count: 3246  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

Objectives: Adherence to preventive drug treatment is a clinical problem and we hypothesized that patients' beliefs about medicines and stroke are associated with adherence. The objective was to examine associations between stroke patients' beliefs about stroke and drug treatment and their adherence to drug treatment.

Design: Cross-sectional questionnaire survey.

Setting: Stroke patients from 25 Swedish hospitals were included.

Measurements: Questionnaires were sent to 989 patients to assess their perceptions about stroke (Brief Illness Perception Questionnaire, Brief IPQ), beliefs about medicines (Beliefs about Medicines Questionnaires, BMQ), and adherence to treatment (Medication Adherence Report Scale, MARS) 3 months after stroke onset. Only patients living at home were included in the analysis. The primary outcome was self reported adherence as measured on MARS. MARS scores were dichotomized into adherent/non-adherent. Background and clinical data from the Swedish Stroke register were included.

Results: Eight hundred eleven patients were still living at home and 595 answered the questionnaire. Complete MARS data was available for 578 patients, and 72 (12.5 %) of these were classified as non-adherent. Non-adherent patients scored lower on positive beliefs as measured on BMQ-Necessity (Odds ratio (OR) = 0.90, 95% CI 0.83–0.98) and BMQ-Benefit (OR = 0.77, 95% CI 0.68–0.87), and higher on negative beliefs as measured on BMQ-Concern (OR = 1.12, 95% CI 1.05–1.21), BMQ-Overuse (OR = 1.29, 95% CI 1.14–1.45), and BMQ-Harm (OR = 1.12, 95% CI 1.01–1.24). The Brief IPQ showed that non-adherent patients believed their current treatment to be less useful ( $p = 0.001$ ).

Conclusions: This study showed associations between Swedish stroke patients' beliefs about medicines and adherence. Positive beliefs were less common and negative more common among non-adherent. To improve adherence, patients' beliefs about medicines should be considered.

## ARTICLE SUMMARY

### Article focus

- Poor patient adherence to secondary preventive drug treatment after stroke is a clinical problem.
- The objectives of this study were to examine stroke patients' beliefs about stroke and drug treatment after stroke, and to investigate if these beliefs are associated with patients' adherence to drug treatment after stroke

### Key messages

- There were associations between stroke patients' beliefs about medicines and non-adherence.
- Non-adherent patients scored lower on positive beliefs about medicines and higher on negative beliefs.
- Patients' personal beliefs need to be considered when prescribing medicines or trying to improve patients' use of medicines.

### Strengths and limitations of this study

- Validated questionnaires have been used to collect data on a large sample of patients.
- Although only a minority of patients reported non-adherent behaviour, associations between beliefs and adherence were statistically significant.
- The cross-sectional design made it impossible to draw conclusions about causality.



## INTRODUCTION

Stroke is the third leading cause of death in Sweden and causes great suffering among survivors and claims vast amounts of resources. Preventive treatment is of great importance, and secondary preventive drug treatment is recommended to most stroke patients to prevent recurrent strokes.[1] Patients' adherence to prescribed long-term and/or preventive treatment has, however, been shown to be low,[2] and this results in poor treatment outcomes in non-adherent patients.[3] A previous study on Swedish stroke patients showed that between 25% and 50% of patients, depending on the type of drug, discontinue secondary preventive drug treatment within 2 years after a stroke.[4]

Many factors have been tested for predictability of adherence.[5] Some treatment or healthcare related factors, such as simplified dosage regimens or satisfaction with health care, have been found to associate with a higher degree of adherence. It has been more difficult to find consistent associations between demographics and psycho-social factors and adherence, possibly because of interactions between factors.[5]

Several theoretical models have been developed to explain associations between psychological factors and health-related behaviour in general and adherence behaviour specifically. The model most often discussed in relation to patient adherence is Howard Leventhal's self-regulatory model (SRM).[6] According to an extended version of the SRM, both beliefs about medicines and illness perceptions are related to adherence.[7-9] Non-adherence is often assumed to be involuntary or unintentional – that patients forget, are unable to handle, or cannot afford the drug – but non-adherence is also quite often based on a decision, sometimes called 'intentional non-adherence'.[10] Intentional non-adherence is based on personal beliefs of possible risks from the disease itself, possible risks from the treatment, and with perceived need of the treatment.

Interventions to improve patients' long-term use of drugs are, although often complex, not very effective.[11] Preventive drug therapy after stroke is both a long-term and asymptomatic treatment, and to improve adherence it might be important to consider patients' beliefs about medicines and stroke. We hypothesized that patients' beliefs about medicines and stroke are associated with drug adherence among stroke patients. The objectives of this study were to examine stroke patients' beliefs about stroke and drug treatment after stroke, and to investigate if these beliefs are associated with patients' adherence to drug treatment after stroke.

## METHODS

In this cross-sectional study, questionnaire data on attitudes and beliefs about stroke and medicines has been merged with clinical data from the Swedish stroke register (Riks-Stroke). The study questionnaire and the follow-up questionnaire from the stroke register were sent to the patients 3 months after stroke onset.

The participants in this study were all stroke patients who were registered in Riks-Stroke from December 2011 to March 2012. Riks-Stroke was established in 1994, and since 1998 all hospitals that admit acute stroke patients report to the register.[12] In 2011, the register was estimated to cover 90.5% of all stroke cases in Sweden. All 74 hospitals participating in the stroke register were invited to participate and 25 of the hospitals volunteered. The participating hospitals are situated in 15 of the 21 counties/regions in Sweden and represent both rural and urban areas. University hospitals (n = 4), large non-university hospitals (n = 11), and community hospitals (n = 10) were included.

Only patients who, according to the stroke register, were living at home 3 months after they had suffered their stroke were included in the study. For other patients, such as patients living in institutions, non-individual routines were assumed to have too much of an effect on patient adherence.

Background information on the patient and information about the stroke event was obtained from Riks-Stroke through the patient's personal identification number. Intracerebral haemorrhages, cerebral infarctions, and strokes not specified as haemorrhage or infarction (diagnosis codes ICD-10: I61, I63, and I64) are included in Riks-Stroke. The register contains patient-related information and data about care both from the acute phase of the stroke and from a 3-month follow-up questionnaire.

Data on patients' beliefs about stroke, medicines, and patient adherence to treatment were collected through a questionnaire consisting of 35 questions with answers on Likert-type scales. The following three validated questionnaires were used in our study: the Brief Illness Perception Questionnaire (Brief IPQ), the Beliefs about Medicines Questionnaires (BMQ), and the Medication Adherence Report Scale (MARS).

The Brief IPQ consists of nine questions aimed at examining patients' cognitive and emotional ideas about their disease.[13] The Brief IPQ has been tested in several illness groups and shows reliability and validity.[13] For this study, questions have been modified to be more specific to stroke (e.g. replacing the word "illness" with "stroke"), and the face validity of the translation to Swedish was tested on a sample of Swedish stroke patients. The answers to the first eight questions in the Brief IPQ that were used in this study (Table 1) were rated on a scale from 0 to 10. The last question in the Brief IPQ is open-ended to assess what patients believe are the three most important causes of their stroke, but this question would have required qualitative analysis and, therefore, was not used.

**Table 1** Back-translation of the questions in the modified Brief Illness Perception Questionnaire

Question Nr	Back-translation of the questions in the modified Brief Illness Perception Questionnaire
1	How much does your stroke affect your life?
2	How long do you think your stroke will affect you?

3	How much control do you feel you have over your stroke/stroke symptoms?
4	How much do you think your treatment can prevent another stroke?
5	How much do you experience symptoms from your stroke?
6	How concerned are you about having another stroke?
7	How much do you think you know about stroke?
8	How much does your stroke affect you emotionally? (e.g. does it make you angry, scared, upset or depressed?)

The BMQ has been developed to assess personal beliefs about medicines.[14, 15] BMQ-Specific assesses patients' beliefs about drugs prescribed for their personal use, and BMQ-General assesses beliefs about medicines in general. The BMQ-Specific has two subscales (*Necessity* and *Concern*) with five questions each, and the BMQ-General has three subscales (*Harm*, *Overuse* and *Benefit*) with four questions each. Representations of the different BMQ subscales are presented in Table 2. Answers to all 22 questions were scored on a 5-point Likert scale (1 = strongly disagree, 2 = disagree, 3 = uncertain, 4 = agree, 5 = strongly agree) and a total score per BMQ scale was calculated. For individuals with one or more answers missing, the total scores of the corresponding BMQ subscales were excluded.

**Table 2** Representations of the different questionnaire subscales used to assess patients' beliefs about medicines.

BMQ-Subscales	Representation of personal beliefs
BMQ-Specific	
- Necessity	perceived personal need for medicine to maintain or improve own health
- Concern	perceived concern about negative effects of their own use of medicines
BMQ-General	
- Harm	perceived harmful nature of medicines in general
- Overuse	perceived notion that doctors overuse or put too much trust in medicines
- Benefit	perceived potential benefits of medicines in general

Self-rated non-adherence to treatment was the main outcome of this study, and this was assessed using the 5-item version of the MARS.[16] MARS and BMQ have previously been translated into Swedish with back-translation approved by the developer of the original questionnaires. The MARS-5 consists of five general statements about non-adherent behaviour (*I forget to take my medicines, I alter the dose of my medicines, I stop taking my medicines for a while, I decide to miss out a dose, I take less than instructed*) answered on a 5-point Likert scale (1 = *always*, 2 = *often*, 3 = *sometimes*, 4 = *rarely*, 5 = *never*). The outcome variable was calculated as the total score on the MARS-5 and a score of 5–22 was considered non-adherent and a score of 23–25 was considered adherent. Sensitivity analyses were performed with MARS scores 21 and 20 as the cut-off for non-adherence. Individuals missing one or more answers on the MARS were excluded from the analysis because their total MARS score would not be comparable with the rest of the study population.

#### Power calculation

1  
2  
3 The main hypothesis of the study was that there is a difference in BMQ between adherent and non-  
4 adherent patients as defined by their MARS score. Including 388 individuals, of whom approximately  
5 half are adherent, gives the study 80% power to detect a difference of 0.2 (BMQ) between adherent  
6 and non-adherent patients if the standard deviation for the difference is 0.7. This calculation is based  
7 on a 2-tailed t-test and a significance level of 0.05. To compensate for an ordinal response variable  
8 (BMQ) and a possible non-response (up to 40%), at least 650 individuals needed to be sent a  
9 questionnaire.  
10

### 11 **Statistical analyses**

12  
13 Differences in background and medical factors were tested using the Chi-squared test. The factors  
14 tested were age, sex, type of stroke, low level of consciousness at admission to hospital, history of  
15 stroke, and stroke unit treatment, and the factors from the 3 month follow-up were living alone,  
16 smoking, self-reported bad general health, self-reported depression, whether dependent on help  
17 and/or support from relatives, having had a return visit to a doctor and/or nurse, and self-reported  
18 difficulties with memory. Age was coded as <75 years or ≥75 years, sex as “Man” or “Woman”, type  
19 of stroke as “Haemorrhage” or “Other”, and difficulties with memory as “Never/almost never”,  
20 “Sometimes”, and “Often/constantly”. Answers to all other factors were coded “No” or “Yes”.  
21 Factors with a statistically significant difference ( $p < 0.05$ ) between adherent and non-adherent  
22 patients were included in multivariable analyses.  
23

24  
25 The results for individual Brief IPQ questions and BMQ subscales were calculated as medians and  
26 inter quartile ranges (IQR). Mann-Whitney U tests were used to test differences between adherent  
27 and non-adherent patients in illness perceptions (individual items in the Brief IPQ) and beliefs about  
28 medicines (BMQ subscales).  
29

30  
31 Besides descriptive analyses with group comparisons, the statistical analysis also included  
32 multivariable methods to control for several factors simultaneously. The outcome measure (self  
33 reported adherence as measured with MARS) was dichotomised, and logistic regression was used for  
34 multivariable analyses. For categorical co-variables, “<75 years”, “Man”, “Haemorrhage”,  
35 “Never/almost never” having difficulties with memory, and “No” were chosen as reference  
36 categories. After checking the linearity assumption, the Brief IPQ scores and the BMQ scores were  
37 included as continuous covariates in the logistic regression models. Results are presented as odds  
38 ratios (OR) with 95% confidence intervals (CI). Only one BMQ scale at a time was included in the  
39 regression models because the objective was to study associations between different beliefs about  
40 medicines and adherence. Spearman’s correlation coefficient was used to test for correlations  
41 between the different BMQ subscales.  
42

43  
44 An analysis of non-responders was performed using data from the stroke register. Non-responders  
45 were compared by Chi-squared test to responders in regards to the same background and medical  
46 factors as described above.  
47

48  
49 Internal consistency within BMQ subscales and MARS was measured with Cronbach’s alpha. A high  
50 value indicates high intercorrelation between items in a subscale, and values over 0.7 are considered  
51 acceptable.[17]  
52

53  
54 Statistical analyses were performed using IBM SPSS Statistics version 21.0  
55  
56  
57  
58  
59  
60

**Ethics**


This study was approved by the Ethical Review Board at Umeå University on January 17, 2012, Reg. No 2011-375-31M.

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## RESULTS

The study questionnaire was sent to 989 patients who were discharged from hospital to their own homes. Of these, 811 were living at home 3 months after their stroke and were included for further analysis. Out of these 811, 595 (73.4 %) responded to the questionnaire. Figure 1 shows a flowchart of hospitals and patients in the study.



**Figure 1** Flowchart of hospitals and patients in the study

Five hundred seventy-eight patients had complete answers to the adherence questions (MARS), and 72 (12.5 %) of these were classified as non-adherent. The proportion of patients who self-reported non-adherent behaviour (the answers “sometimes”, “often”, and “always”) on any of the MARS statements were 9.7% for “I forget to take my medicines”, 12.8% for “I alter the dose of my medicines”, 2.2% for “I stop taking my medicines for a while”, 8.4% for “I decide to miss out on a dose”, and 4.5% for “I take less than instructed”.

Differences in background and medical factors between adherent and non-adherent patients are presented in Table 3. Non-adherent patients were more often men, not treated in stroke units, dependent on the help and support from relatives, had a history of stroke, and more often self-reported memory difficulties compared to adherent patients.

**Table 3** Patient characteristics by level of adherence. Chi-squared test of differences between non-adherent and adherent patients.

<i>Variable/Characteristic</i>	<i>Non-adherent (n = 72)</i>	<i>Adherent (n = 506)</i>	<i>p</i>
Age, n (%)			0.341
- < 75 years	38 (11.3)	297 (88.7)	
- ≥ 75 years	34 (14.0)	209 (86.0)	
Sex, n (%)			0.042
- Men	51 (14.7)	295 (85.3)	
- Women	21 (9.1)	211 (90.9)	
Type of stroke, n (%)			0.325
- Haemorrhage	3 (7.5)	37 (92.5)	
- Other (ICD10 I63 + I64)	69 (12.8)	469 (87.2)	
Low level of consciousness at admission, n (%)			0.770
- No	68 (12.4)	480 (87.6)	
- Yes (Drowsy or unconscious)	4 (14.3)	24 (85.7)	
History of stroke, n (%)			0.010
- No	54 (11.0)	437 (89.0)	
- Yes	18 (20.9)	68 (79.1)	
Treated in stroke unit, n (%)			0.016
- No	6 (30.0)	14 (70.0)	
- Yes	66 (11.8)	491 (88.2)	
<b>3 months follow-up</b>			
Living alone, n (%)			0.241
- No	45 (11.2)	357 (88.8)	
- Yes	25 (14.7)	145 (85.3)	
Smoking, n (%)			0.303
- No	64 (12.1)	463 (87.9)	
- Yes	8 (17.4)	38 (82.6)	
Self-reported bad general health, n (%)			0.210
- No	56 (11.6)	426 (88.4)	
- Yes	14 (16.5)	71 (83.5)	
Self-reported depression, n (%)			0.147
- No	51 (11.4)	396 (88.6)	
- Yes	18 (16.5)	91 (83.5)	
Dependent on help/support from relatives, n (%)			0.015
- No	26 (9.0)	263 (91.0)	
- Yes	43 (15.8)	230 (84.2)	
Return visit, n (%)			0.521
- No	7 (9.9)	64 (90.1)	
- Yes	60 (12.5)	419 (87.5)	
Difficulties with memory, n (%)			0.014
- Never or almost never	25 (11.1)	200 (88.9)	
- Sometimes	29 (10.7)	241 (89.3)	
- Often or constantly	17 (23.0)	57 (77.0)	



Internal consistency for BMQ subscales and MARS, measured by Cronbach's alpha, showed highest values for the BMQ-Specific scales (Table 4).

**Table 4** Descriptive of questionnaire scales used.

<i>Scale</i>	<i>Number of items in scale</i>	<i>Range of scores</i>	<i>Cronbach's alpha</i>
BMQ-Specific			
- Necessity	5	5-25	0.823
- Concern	5	5-25	0.818
BMQ-General			
- Overuse	4	4-20	0.684
- Harm	4	4-20	0.647
- Benefit	4	4-20	0.697
MARS	5	5-25	0.723

Results from question 4 on the modified Brief IPQ "How much do you think your current treatment can prevent another stroke?" showed that non-adherent patients believed their current treatment to be less useful (median = 5 (IQR 3–7)) compared to adherent patients (median = 7 (IQR 5–8)) and this difference was statistically significant ( $p = 0.001$ ). No other Brief IPQ-question showed a significant difference between adherent and non-adherent patients.

Results for total BMQ scale scores are presented and compared in Table 5. All BMQ subscales except *Necessity* showed statistically significant differences between adherent and non-adherent patients in the univariate analysis.

**Table 5** Scale score medians and inter quartile ranges (IQR) for the scales used to assess patients' beliefs about medicines (BMQ), comparing non-adherent with adherent patients.

<i>Variable</i>	<i>Valid cases (n = 578)</i>	<i>Scale score median (IQR)</i>		<i>Mann-Whitney U test (p-value)</i>	<i>Adjusted with multivariable logistic regression* OR for a one-unit increase (95% CI)</i>
		<i>Non-Adherent (n = 72)</i>	<i>Adherent (n = 506)</i>		
BMQ-Specific					
- Necessity	558	18 (16-20)	19 (17-21)	0.079	0.90 (0.83-0.98)
- Concern	552	14 (11-17)	12 (9-15)	<0.001	1.12 (1.05-1.21)
BMQ-General					
- Overuse	556	13 (11-14)	11 (10-13)	<0.001	1.29 (1.14-1.45)
- Harm	544	11 (9-12.25)	10 (8-12)	0.038	1.12 (1.01-1.24)
- Benefit	560	16 (14-16)	16 (15-18)	<0.001	0.77 (0.68-0.87)

\* Adjusted for age, sex, history of stroke, if treated in stroke unit, dependent on help/support from relatives, difficulties with memory, Brief IPQ – question 4, and respective BMQ subscale.

The multivariable logistic regression models showed associations between all five subscales on beliefs about medicines and non-adherence to treatment. Non-adherent stroke patients had lower



scores on the positive statements about medicines as measured on both BMQ subscales *Necessity* (OR = 0.90, 95% CI 0.83–0.98) and *Benefit* (OR = 0.77, 95% CI 0.68–0.87). Non-adherent patients also scored higher on the negative beliefs as measured on BMQ subscales *Concern* (OR = 1.12, 95% CI 1.05–1.21), *Harm* (OR = 1.12, 95% CI 1.01–1.24), and *Overuse* (OR = 1.29, 95% CI 1.14–1.45). Correlations between the different BMQ subscales were statistically significant except between *Necessity* and *Concern* (Table 6).

**Table 6** Correlation matrix for different scales used to test beliefs about medicines. Spearman's correlation coefficient (p-value).

	BMQ- Necessity	BMQ- Concern	BMQ- Overuse	BMQ- Harm	BMQ- Benefit
BMQ- Necessity	1				
BMQ- Concern	-0.075 (0.080)	1			
BMQ- Overuse	-0.226 (<0.001)	0.434 (<0.001)	1		
BMQ- Harm	-0.185 (<0.001)	0.444 (<0.001)	0.558 (<0.001)	1	
BMQ- Benefit	0.315 (<0.001)	-0.287 (<0.001)	-0.322 (<0.001)	-0.362 (<0.001)	1

Out of the 356 non-responders, 216 were still living at home 3 months after the stroke onset. Patients who responded to the questionnaire were compared to non-responders in terms of background and medical factors (the same factors were tested as in Table 3). The results of this analysis showed that non-responders more often had a history of stroke ( $p = 0.018$ ), self-reported bad general health ( $p = 0.001$ ), depression ( $p = 0.012$ ), were living alone ( $p = <0.001$ ), and were smoking ( $p = 0.046$ ). Non-responders had been treated in university hospitals ( $n = 27$ ), large non-university hospitals ( $n = 140$ ), and community hospitals ( $n = 49$ ).

The variables from Riks-Stroke with the highest numbers of missing data were, for responders ( $n = 595$ ), return visits ( $n = 28$ ) and self-reported depression ( $n = 22$ ), and for non-responders ( $n = 216$ ), return visits ( $n = 18$ ) and self-reported depression ( $n = 14$ ).

Sensitivity analyses with lower MARS scores (21 and 20) as the cut-off for non-adherence showed lower levels of non-adherence (8.8% and 5.7%, respectively) and fewer statistically significant differences in patient characteristics between adherent and non-adherent patients. Differences in BMQ between adherent and non-adherent patients remained with both cut-offs except for BMQ-Concern and BMQ-Harm when a MARS score of 20 was used as the cut-off (data not shown).

## DISCUSSION

This study showed associations between patients' beliefs about stroke and medicines and self-rated non-adherence to drug treatment. Only 12.5% of patients were classified as non-adherent 3 months after stroke. Beliefs about medicines showed stronger associations to adherence compared to illness perceptions, and non-adherent patients scored lower on positive beliefs about medicines and higher on negative beliefs.

Because having a stroke is often a serious and frightening experience, a low level of non-adherence to preventive drugs is expected only 3 months after stroke. Among the minority of patients reporting non-adherent behaviour, we showed an association between personal beliefs and adherence relatively soon after stroke. This indicates that patients who self-reported non-adherence early were patients for whom non-adherence was based on personal beliefs in medication harm and low beliefs in personal need for drugs.

Validated questionnaires have been used to collect data on a rather large sample of patients. None of the questionnaires have been validated specifically for stroke, but both MARS and BMQ have been used in studies of a range of conditions that included stroke[9, 18, 19] and Brief IPQ has been tested in myocardial infarction and diabetes.[13] The study had a high power. The power calculation estimated that the questionnaire had to be sent to at least 650 patients. Because all hospitals were invited, and the number and size of volunteering hospitals were not known in advance, those volunteering made it possible to include more than 650 patients.

There is no gold standard method to measure adherence.[20] Self-reported adherence measures are sometimes said to overestimate adherence because of self-presentation and recall bias, but a metaanalysis has shown that this is not always the case.[20] Instructions in the questionnaire were formulated to encourage patients to answer truthfully and assured the patients that their answers would not affect future care. MARS has been used in many studies of several long-term illnesses, including chronic pain,[21] asthma,[7] secondary prevention of coronary heart disease,[9] and stroke.[19] The only other option for measuring adherence would have been prescription refill data, but because Swedish prescriptions generally cover a time period of 3 months, only patients who did not buy a drug at all within the 3 months of having their stroke (primary non-adherence) would be classified as non-adherent. The proportion of primary non-adherence has been shown to be low (4–11 %) for secondary prevention of stroke.[22] Questions on adherence were not directed toward specific drugs or treatments, and if patients were selectively adherent this was not captured. The cross-sectional design of this study made it impossible to draw conclusions about causality or to measure changes in behaviour.

In a previous study, non-adherence was found to be higher in non-responders compared to responders.[23] Because adherence was self-reported in this study, non-adherence could not be estimated for non-responders. However, according to data from the stroke register non-responders more often reported poor general health or depression, more often had had a previous stroke, and more often were living alone. There was a larger proportion non-adherent patients among those with a history of stroke compared to first-time strokes. [Patients with a history of stroke might have different opinions or perceptions about stroke at this early point after stroke \(3 months\). With the larger proportion of patients with a previous stroke among non-responders, this could have affected](#)

1  
2  
3 | [the results on illness perceptions](#). There could also have been other differences between responders  
4 and non-responders that were not tested in this study that could have affected the results.  
5

6  
7 In a study from the UK on predictors of adherence to secondary preventive treatment after stroke,  
8 associations between BMQ-specific (*Necessity* and *Concern*) and adherence were tested. Statistically  
9 significant associations were found with subscale *Concern*.<sup>[19]</sup> A study on secondary prevention of  
10 coronary heart disease found adherence to be related to both BMQ subscales *Necessity* and  
11 *Concern*.<sup>[9]</sup> Several studies have also shown similar results with stronger associations between  
12 adherence behaviour and beliefs about medicines than with illness perceptions.<sup>[7-9]</sup> This is also in  
13 line with the extended self-regulatory model according to which illness perceptions could be directly  
14 related to adherence but also, and often stronger, indirectly through associations between illness  
15 perception and beliefs about medicines.<sup>[21]</sup> The full model has not been tested in this study. This  
16 study was performed in Sweden, and although different personal beliefs sometimes reflect cultural  
17 differences the associations found in this sample were consistent with results from studies in other  
18 countries.<sup>[8, 9, 24]</sup>  
19  
20

21  
22 In this study MARS scores were dichotomized, but in some studies they have been used as a  
23 continuous variable. The chosen cut-off allowed adherent patients to answer “rarely” on two  
24 questions or “sometimes” on one, and this cut-off has been used in other studies.<sup>[25]</sup> Changing the  
25 cut-off from 22 to 21 or 20 decreased the number of patients classified as non-adherent but only  
26 marginally changed the associations between personal beliefs and self-rated adherence.  
27  
28

29  
30 Self-rated non-adherence in this sample was quite low 3 months after stroke, but in other studies  
31 non-adherence has been shown to increase over time.<sup>[4]</sup> Declining adherence is, of course, a  
32 problem but secondary prevention is also important early after stroke.<sup>[26, 27]</sup> Because the results  
33 from this study and other studies showed associations between beliefs about medicines and  
34 adherence to treatment, it might be important to incorporate these questions into discussions with  
35 patients about preventing further illness. maybe even using questions from the BMQ. It seems  
36 important for eClinical staff should to try to assess patients’ views of medicines, not just informing  
37 patients about medicines or trying to convince patients to use medicines. Giving patients information  
38 and instructions is sometimes considered enough, but information is not the same as education.  
39 Patients with negative beliefs about medicines need to be identified, and questions from the BMQ  
40 could be used for this. Because preventive drugs are important early after stroke, it is important to  
41 identify these patients early. Patients with a history of stroke or patients who have used the drugs for  
42 other reasons before stroke could be more inclined to have opinions about stroke and medicines  
43 already during hospital stay. However, most patients could briefly, already at discharge from  
44 hospital, be asked about their opinion about using preventive drugs. Most interventions that have  
45 shown effect on patient adherence to long-term treatments are complex and include combinations  
46 of several steps e.g. information, self-monitoring, counselling, supportive care.<sup>[11]</sup> These more  
47 complex interventions are likely more suitable for follow-up visits to hospitals or primary care visits,  
48 possibly led by specially trained nurses or trained clinical pharmacists, then for the acute inpatient  
49 phase. Patients’ perceptions or behaviours are rarely discussed in clinical guidelines.  
50  
51  
52  
53  
54

55 In conclusion, although self-rated non-adherence 3 months after stroke was low, associations  
56 between patients’ beliefs about medicines and non-adherence were seen in this sample of Swedish  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

stroke patients. Patients’ personal beliefs need to be considered when prescribing medicines or trying to improve patients’ use of medicines.

For peer review only

1  
2  
3 **Acknowledgments:** The authors would like to thank all of the stroke patients who answered our  
4 questionnaire, and the Riks-Stroke contacts in all 25 hospitals that helped us with sending and  
5 collecting the questionnaires. The authors are also thankful to Riks-Stroke for providing the database  
6 and to Professor Rune Dahlqvist for his comments on the manuscript.  
7

8  
9 **Contributors:** All authors contributed to the article by participating in the design (MS, ME, ELG),  
10 acquisition of data (MS, ELG), analysis or interpretation of data (MS, ME, ELG), drafting the  
11 manuscript (MS, ELG) and revising it critically (MS, ME, ELG), and approving the final manuscript (MS,  
12 ME, ELG).  
13

14 **Competing interests:** None  
15

16 **Funding:** Riks-Stroke, the Swedish Stroke Register, is funded by the National Board of Health and  
17 Welfare and the Swedish Association of Local Authorities and Regions. For this study, the authors  
18 received grant support from Västerbotten County Council and the Northern Swedish Stroke Fund.  
19

20 **Data sharing statement:** No additional data are available.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Socialstyrelsen. Nationella riktlinjer för strokesjukvård 2009 - Stöd för styrning och ledning. (National guidelines for stroke care 2009) (in Swedish). The Swedish National Board of Health and Welfare, Stockholm. Stockholm 2009.
2. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization 2003.
3. Robin DiMatteo MP, Giordani PJMA, Lepper HSP, et al. Patient Adherence and Medical Treatment Outcomes: A Meta-Analysis. *Med Care*. 2002;**40**:794-811.
4. Glader E-L, Sjölander M, Eriksson M, et al. Persistent Use of Secondary Preventive Drugs Declines Rapidly During the First 2 Years After Stroke. *Stroke*. 2010;**41**:397-401.
5. Jin J, Sklar GE, Oh VMS, et al. Factors affecting therapeutic compliance: A review from the patient's perspective *Therapeutics and Clinical Risk Management*. 2008;**4**:269-86.
6. Leventhal H, Diefenbach M, Leventhal E. Illness cognition: Using common sense to understand treatment adherence and affect cognition interactions. *Cognitive Therapy and Research*. 1992;**16**:143-63.
7. Horne R, Weinman J. Self-regulation and Self-management in Asthma: Exploring The Role of Illness Perceptions and Treatment Beliefs in Explaining Non-adherence to Preventer Medication. *Psychology & Health*. 2002;**17**:17-32.
8. Ross S, Walker A, MacLeod MJ. Patient compliance in hypertension: role of illness perceptions and treatment beliefs. *J Hum Hypertens*. 2004;**18**:607-13.
9. Byrne M, Walsh J, Murphy AW. Secondary prevention of coronary heart disease: Patient beliefs and health-related behaviour. *J Psychosom Res*. 2005;**58**:403-15.

10. Horne R. Beliefs and adherence to treatment: the challenge for research and clinical practice. In: Halligan P, Aylward M, ed. *The Power of Belief*. Oxford: Oxford University Press, 2006.
11. Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. *Cochrane Database of Systematic Reviews*. 2008:CD000011.
12. Asplund K, Hulter Åsberg K, Appelros P, et al. The Riks-Stroke story: building a sustainable national register for quality assessment of stroke care. *International Journal of Stroke*. 2011;**6**:99-108.
13. Broadbent E, Petrie KJ, Main J, et al. The Brief Illness Perception Questionnaire. *J Psychosom Res*. 2006;**60**:631-7.
14. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication. *Psychology & Health*. 1999;**14**:1-24.
15. Horne R, Frost S, Hankins M, et al. "In the eye of the beholder": pharmacy students have more positive perceptions of medicines than students of other disciplines. *International Journal of Pharmacy Practice*. 2001;**9**:85-9.
16. Mahler C, Hermann K, Horne R, et al. Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the Medication Adherence Report Scale (MARS) in Germany. *J Eval Clin Pract*. 2010;**16**:574-9.
17. Tavakol M, Dennick R. Making sense of Cronbach's alpha. *Int J Med Educ*. 2011;**2**:53-5.
18. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. *J Psychosom Res*. 1999;**47**:555-67.

- 1  
2  
3 19. O'Carroll R, Whittaker J, Hamilton B, et al. Predictors of Adherence to Secondary  
4 Preventive Medication in Stroke Patients. *Ann Behav Med.* 2011;**41**:383-90.  
5  
6  
7  
8 20. DiMatteo MR. Variations in Patients' Adherence to Medical Recommendations: A  
9 Quantitative Review of 50 Years of Research. *Med Care.* 2004;**42**:200-9.  
10  
11  
12  
13 21. Nicklas LB, Dunbar M, Wild M. Adherence to pharmacological treatment of non-  
14 malignant chronic pain: The role of illness perceptions and medication beliefs. *Psychology & Health.*  
15  
16  
17 2010;**25**:601-15.  
18  
19  
20  
21 22. Sjölander M, Eriksson M, Glader E-L. Few sex differences in the use of drugs for  
22 secondary prevention after stroke: a nationwide observational study. *Pharmacoepidemiology and*  
23  
24  
25  
26 2012;**21**:911-9.  
27  
28  
29 23. Gadkari AS, Pedan A, Gowda N, et al. Survey Nonresponders to a Medication-beliefs  
30 Survey Have Worse Adherence and Persistence to Chronic Medications Compared With Survey  
31  
32  
33 Responders. . *Medical Care* 2011;**49** 956-61.  
34  
35  
36 24. Menckeberg TT, Bouvy ML, Bracke M, et al. Beliefs about medicines predict refill  
37 adherence to inhaled corticosteroids. *J Psychosom Res.* 2008;**64**:47-54.  
38  
39  
40  
41 25. Mårdby A-C, Åkerlind I, Jörgensen T. Beliefs about medicines and self-reported  
42 adherence among pharmacy clients. *Patient Educ Couns.* 2007;**69**:158-64.  
43  
44  
45  
46 26. Sanossian N, Ovbiagele B. The risk of stroke within a week of minor stroke or transient  
47 ischemic attack. *Expert Opinion on Pharmacotherapy.* 2008;**9**:2069-76.  
48  
49  
50  
51 27. Field T, Benavente O. Current Status of Antiplatelet Agents to Prevent Stroke. *Current*  
52  
53  
54  
55  
56  
57  
58  
59  
60